evidence_id	assertion_id	disorder_id	disorder_name	source_file	section	section_index	path	evidence_index	reference	supports	evidence_source	snippet	explanation	raw_json
83	91	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	prevalence	0	evidence	0	PMID:35297258	SUPPORT		Amyloidosis is a systemic disease characterized by extracellular deposition of amyloid protein, most commonly in the heart and kidney. Hepatic amyloidosis is a rare form of presentation that ranges from mild hepatomegaly and altered liver biochemical tests to acute liver failure.	The reference indicates that amyloidosis, including ATTR amyloidosis, is rare, supporting the statement that ATTR amyloidosis is rare globally.	"{""explanation"": ""The reference indicates that amyloidosis, including ATTR amyloidosis, is rare, supporting the statement that ATTR amyloidosis is rare globally."", ""reference"": ""PMID:35297258"", ""snippet"": ""Amyloidosis is a systemic disease characterized by extracellular deposition of amyloid protein, most commonly in the heart and kidney. Hepatic amyloidosis is a rare form of presentation that ranges from mild hepatomegaly and altered liver biochemical tests to acute liver failure."", ""supports"": ""SUPPORT""}"
84	91	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	prevalence	0	evidence	1	PMID:37907148	SUPPORT		CARS aims to describe the natural history of CA with attention to clinical and diagnostic variables at the time of diagnosis, real-world treatment patterns, and associated outcomes of patients in a diverse cohort that is more representative of the at-risk population than that described in CA clinical trials.	The reference discusses the CARS registry, which includes a diverse cohort of patients with cardiac amyloidosis, including ATTR amyloidosis, indicating that it is a condition under study due to its rarity and complexity.	"{""explanation"": ""The reference discusses the CARS registry, which includes a diverse cohort of patients with cardiac amyloidosis, including ATTR amyloidosis, indicating that it is a condition under study due to its rarity and complexity."", ""reference"": ""PMID:37907148"", ""snippet"": ""CARS aims to describe the natural history of CA with attention to clinical and diagnostic variables at the time of diagnosis, real-world treatment patterns, and associated outcomes of patients in a diverse cohort that is more representative of the at-risk population than that described in CA clinical trials."", ""supports"": ""SUPPORT""}"
148	148	7	Achoo Syndrome	Achoo_Syndrome.yaml	prevalence	0	evidence	0	PMID:30899065	SUPPORT		a Chinese population of 3417 individuals (PSR prevalence at 25.6%)	Large GWAS study in Chinese population reporting prevalence.	"{""explanation"": ""Large GWAS study in Chinese population reporting prevalence."", ""reference"": ""PMID:30899065"", ""snippet"": ""a Chinese population of 3417 individuals (PSR prevalence at 25.6%)"", ""supports"": ""SUPPORT""}"
149	149	7	Achoo Syndrome	Achoo_Syndrome.yaml	prevalence	1	evidence	0	PMID:31287245	SUPPORT		The overall prevalence of PSS was 3.1%.	Lower prevalence in Japanese cohort may reflect survey methodology or population differences.	"{""explanation"": ""Lower prevalence in Japanese cohort may reflect survey methodology or population differences."", ""reference"": ""PMID:31287245"", ""snippet"": ""The overall prevalence of PSS was 3.1%."", ""supports"": ""SUPPORT""}"
182	183	8	Acne Vulgaris	Acne_Vulgaris.yaml	prevalence	0	evidence	0	PMID:28707712	SUPPORT		The overall adjusted prevalence of self-reported acne was 57.8% (95% confidence interval 56.9% to 58.7%).	This European survey reports a high prevalence of acne among adolescents and young adults.	"{""explanation"": ""This European survey reports a high prevalence of acne among adolescents and young adults."", ""reference"": ""PMID:28707712"", ""snippet"": ""The overall adjusted prevalence of self-reported acne was 57.8% (95% confidence interval 56.9% to 58.7%)."", ""supports"": ""SUPPORT""}"
183	184	8	Acne Vulgaris	Acne_Vulgaris.yaml	prevalence	1	evidence	0	PMID:39271178	SUPPORT		"RESULTS: Globally, the age-standardized prevalence rate of acne vulgaris among 
adolescents and young adults increased from 8563.4 per 100 000 population [95% 
uncertainty interval (UI) 7343.5-9920.1] in 1990 to 9790.5 (95% UI 8420.9-11 
287.2) per 100 000 population in 2021, with an AAPC of 0.43 [95% confidence 
interval (CI) 0.41-0.46]."	The 2021 age-standardized prevalence of 9790.5 per 100,000 corresponds to about 9.79%.	"{""explanation"": ""The 2021 age-standardized prevalence of 9790.5 per 100,000 corresponds to about 9.79%."", ""reference"": ""PMID:39271178"", ""snippet"": ""RESULTS: Globally, the age-standardized prevalence rate of acne vulgaris among \nadolescents and young adults increased from 8563.4 per 100 000 population [95% \nuncertainty interval (UI) 7343.5-9920.1] in 1990 to 9790.5 (95% UI 8420.9-11 \n287.2) per 100 000 population in 2021, with an AAPC of 0.43 [95% confidence \ninterval (CI) 0.41-0.46]."", ""supports"": ""SUPPORT""}"
184	185	8	Acne Vulgaris	Acne_Vulgaris.yaml	prevalence	2	evidence	0	PMID:23210645	SUPPORT		Moderate-to-severe acne affects around 20% of young people and severity correlates with pubertal maturity.	This review summarizes the prevalence of moderate-to-severe acne among young people.	"{""explanation"": ""This review summarizes the prevalence of moderate-to-severe acne among young people."", ""reference"": ""PMID:23210645"", ""snippet"": ""Moderate-to-severe acne affects around 20% of young people and severity correlates with pubertal maturity."", ""supports"": ""SUPPORT""}"
263	230	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	prevalence	0	evidence	0	PMID:7851311	REFUTE		Since the recognition of AIDS in 1981, it has become a global pandemic afflicting more than 6 million people worldwide. To date, more than 22 million people are infected with HIV-1, the cause of AIDS, and more than 40 million people may be infected with HIV by the year 2000.	The statement claims a global prevalence of AIDS at 0.7%, whereas the literature indicates a much higher number of people affected, inconsistent with the 0.7% prevalence.	"{""explanation"": ""The statement claims a global prevalence of AIDS at 0.7%, whereas the literature indicates a much higher number of people affected, inconsistent with the 0.7% prevalence."", ""reference"": ""PMID:7851311"", ""snippet"": ""Since the recognition of AIDS in 1981, it has become a global pandemic afflicting more than 6 million people worldwide. To date, more than 22 million people are infected with HIV-1, the cause of AIDS, and more than 40 million people may be infected with HIV by the year 2000."", ""supports"": ""REFUTE""}"
362	270	10	Addison's Disease	Addisons_Disease.yaml	prevalence	0	evidence	0	PMID:27210825	PARTIAL		Diagnosis is often delayed, probably partly because diseases of the adrenal or pituitary region that cause primary AI (PAI) or central AI are relatively rare conditions.	The literature mentions that diseases causing primary or central adrenal insufficiency are relatively rare, but it does not provide a specific percentage or confirm the rarity of Addison's Disease globally.	"{""explanation"": ""The literature mentions that diseases causing primary or central adrenal insufficiency are relatively rare, but it does not provide a specific percentage or confirm the rarity of Addison's Disease globally."", ""reference"": ""PMID:27210825"", ""snippet"": ""Diagnosis is often delayed, probably partly because diseases of the adrenal or pituitary region that cause primary AI (PAI) or central AI are relatively rare conditions."", ""supports"": ""PARTIAL""}"
363	270	10	Addison's Disease	Addisons_Disease.yaml	prevalence	0	evidence	1	PMID:12072049	PARTIAL		We found a higher prevalence of Addison's disease in western Norway than has previously been reported anywhere.	The study indicates a higher prevalence in a specific region (western Norway) but does not provide a global perspective on the rarity of Addison's Disease.	"{""explanation"": ""The study indicates a higher prevalence in a specific region (western Norway) but does not provide a global perspective on the rarity of Addison's Disease."", ""reference"": ""PMID:12072049"", ""snippet"": ""We found a higher prevalence of Addison's disease in western Norway than has previously been reported anywhere."", ""supports"": ""PARTIAL""}"
364	270	10	Addison's Disease	Addisons_Disease.yaml	prevalence	0	evidence	2	PMID:38562931	PARTIAL		Autoimmune Addison's disease (AAD) is a rare but life-threatening endocrine disorder caused by an autoimmune destruction of the adrenal cortex.	The literature confirms that autoimmune Addison's Disease is rare, but it does not specify the percentage or provide a comprehensive global view.	"{""explanation"": ""The literature confirms that autoimmune Addison's Disease is rare, but it does not specify the percentage or provide a comprehensive global view."", ""reference"": ""PMID:38562931"", ""snippet"": ""Autoimmune Addison's disease (AAD) is a rare but life-threatening endocrine disorder caused by an autoimmune destruction of the adrenal cortex."", ""supports"": ""PARTIAL""}"
365	270	10	Addison's Disease	Addisons_Disease.yaml	prevalence	0	evidence	3	PMID:33143829	PARTIAL		Typical and atypical presentations of Addison's disease in children of Pakistani population are defined in this study which may assist in better management of Addison's patients.	The study discusses the presentation of Addison's Disease in a specific population (Pakistani children) but does not address the global rarity of the disease.	"{""explanation"": ""The study discusses the presentation of Addison's Disease in a specific population (Pakistani children) but does not address the global rarity of the disease."", ""reference"": ""PMID:33143829"", ""snippet"": ""Typical and atypical presentations of Addison's disease in children of Pakistani population are defined in this study which may assist in better management of Addison's patients."", ""supports"": ""PARTIAL""}"
431	374	14	Ainhum	Ainhum.yaml	prevalence	0	evidence	0	PMID:12500788	SUPPORT	HUMAN_CLINICAL	Between 1977 and 1999, a total 6000 radiographic studies of the feet were reviewed in a mainly African American population in Chicago, Illinois.	Radiological survey population and timeframe.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Radiological survey population and timeframe."", ""reference"": ""PMID:12500788"", ""snippet"": ""Between 1977 and 1999, a total 6000 radiographic studies of the feet were reviewed in a mainly African American population in Chicago, Illinois."", ""supports"": ""SUPPORT""}"
432	374	14	Ainhum	Ainhum.yaml	prevalence	0	evidence	1	PMID:12500788	SUPPORT	HUMAN_CLINICAL	102 patients were diagnosed with dactylolysis spontanea or ainhum.	Survey reports number of identified ainhum cases.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Survey reports number of identified ainhum cases."", ""reference"": ""PMID:12500788"", ""snippet"": ""102 patients were diagnosed with dactylolysis spontanea or ainhum."", ""supports"": ""SUPPORT""}"
459	398	15	Akinetopsia	Akinetopsia.yaml	prevalence	0	evidence	0	PMID:40605075	SUPPORT	HUMAN_CLINICAL	Since akinetopsia was first described in 1911, only a handful of cases have been studied.	This review emphasizes the rarity of akinetopsia and the limited number of documented cases.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This review emphasizes the rarity of akinetopsia and the limited number of documented cases."", ""reference"": ""PMID:40605075"", ""snippet"": ""Since akinetopsia was first described in 1911, only a handful of cases have been studied."", ""supports"": ""SUPPORT""}"
460	398	15	Akinetopsia	Akinetopsia.yaml	prevalence	0	evidence	1	PMID:37938052	SUPPORT	HUMAN_CLINICAL	Selective motion blindness, also known as akinetopsia, is infrequently reported in the literature.	This systematic review notes that akinetopsia is infrequently reported, supporting rarity.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This systematic review notes that akinetopsia is infrequently reported, supporting rarity."", ""reference"": ""PMID:37938052"", ""snippet"": ""Selective motion blindness, also known as akinetopsia, is infrequently reported in the literature."", ""supports"": ""SUPPORT""}"
557	433	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	prevalence	0	evidence	0	PMID:23159715	NO_EVIDENCE		It was estimated that in 2010 there were 36.5 million people living with dementia, with 7.7 million new cases yearly and a new case of dementia every 4 sec.	The literature provides global prevalence data for dementia but does not specify a percentage of 5.8% for Alzheimer's disease.	"{""explanation"": ""The literature provides global prevalence data for dementia but does not specify a percentage of 5.8% for Alzheimer's disease."", ""reference"": ""PMID:23159715"", ""snippet"": ""It was estimated that in 2010 there were 36.5 million people living with dementia, with 7.7 million new cases yearly and a new case of dementia every 4 sec."", ""supports"": ""NO_EVIDENCE""}"
558	433	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	prevalence	0	evidence	1	PMID:38008402	NO_EVIDENCE		According to the facts and figures 2023stated that 6.7 million Americans over the age of 65 have Alzheimer's disease (AD).	The literature provides the number of Americans with Alzheimer's disease but does not specify a global percentage of 5.8%.	"{""explanation"": ""The literature provides the number of Americans with Alzheimer's disease but does not specify a global percentage of 5.8%."", ""reference"": ""PMID:38008402"", ""snippet"": ""According to the facts and figures 2023stated that 6.7 million Americans over the age of 65 have Alzheimer's disease (AD)."", ""supports"": ""NO_EVIDENCE""}"
777	602	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	prevalence	0	evidence	0	PMID:30957430	REFUTE		Among this cohort in 2000-2015, 33 cases of incident APS, as defined by the Sydney criteria, were identified... The estimated prevalence of APS was 50 (95% CI 42-58) per 100,000 population, and was similar in both sexes.	The prevalence of APS is reported as 50 per 100,000 population, which translates to 0.05%. However, this value is for all types of APS, not exclusively primary APS.	"{""explanation"": ""The prevalence of APS is reported as 50 per 100,000 population, which translates to 0.05%. However, this value is for all types of APS, not exclusively primary APS."", ""reference"": ""PMID:30957430"", ""snippet"": ""Among this cohort in 2000-2015, 33 cases of incident APS, as defined by the Sydney criteria, were identified... The estimated prevalence of APS was 50 (95% CI 42-58) per 100,000 population, and was similar in both sexes."", ""supports"": ""REFUTE""}"
778	602	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	prevalence	0	evidence	1	PMID:31951187	SUPPORT		28.4% of patients had primary while, 71.6% of patients had secondary APS.	The study notes that 28.4% of the cohort had primary APS, reaffirming the overall distribution of APS cases. Although it does not directly state the global prevalence per 100,000, it supports the distinction between primary and secondary APS.	"{""explanation"": ""The study notes that 28.4% of the cohort had primary APS, reaffirming the overall distribution of APS cases. Although it does not directly state the global prevalence per 100,000, it supports the distinction between primary and secondary APS."", ""reference"": ""PMID:31951187"", ""snippet"": ""28.4% of patients had primary while, 71.6% of patients had secondary APS."", ""supports"": ""SUPPORT""}"
826	640	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	prevalence	0	evidence	0	PMID:23748068	SUPPORT		Aromatase deficiency (AD) is a rare autosomal recessive inheritance syndrome. Its worldwide incidence is unknown, and there are few case reports in the literature.	The literature explicitly states that Aromatase Deficiency is rare with limited cases reported globally.	"{""explanation"": ""The literature explicitly states that Aromatase Deficiency is rare with limited cases reported globally."", ""reference"": ""PMID:23748068"", ""snippet"": ""Aromatase deficiency (AD) is a rare autosomal recessive inheritance syndrome. Its worldwide incidence is unknown, and there are few case reports in the literature."", ""supports"": ""SUPPORT""}"
1111	823	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	prevalence	0	evidence	0	PMID:34269512	NO_EVIDENCE		The combined frequencies of autosomal recessive diseases were estimated to be 26.39/10,000 (or ~0.26%).	The study provides the combined frequencies of autosomal recessive diseases but does not specifically mention the prevalence of Axenfeld-Rieger syndrome.	"{""explanation"": ""The study provides the combined frequencies of autosomal recessive diseases but does not specifically mention the prevalence of Axenfeld-Rieger syndrome."", ""reference"": ""PMID:34269512"", ""snippet"": ""The combined frequencies of autosomal recessive diseases were estimated to be 26.39/10,000 (or ~0.26%)."", ""supports"": ""NO_EVIDENCE""}"
1112	823	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	prevalence	0	evidence	1	PMID:33762894	NO_EVIDENCE		Aarskog-Scott syndrome is a genetically and clinically heterogeneous rare condition caused by a pathogenic variant in the FGD1 gene.	The study focuses on Aarskog-Scott syndrome and does not provide information on the prevalence of Axenfeld-Rieger syndrome.	"{""explanation"": ""The study focuses on Aarskog-Scott syndrome and does not provide information on the prevalence of Axenfeld-Rieger syndrome."", ""reference"": ""PMID:33762894"", ""snippet"": ""Aarskog-Scott syndrome is a genetically and clinically heterogeneous rare condition caused by a pathogenic variant in the FGD1 gene."", ""supports"": ""NO_EVIDENCE""}"
1113	823	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	prevalence	0	evidence	2	PMID:37684520	NO_EVIDENCE		Marfan syndrome (MFS) is an autosomal dominant condition characterized by aortic aneurysm, skeletal abnormalities, and lens dislocation, and is caused by variants in the FBN1 gene.	The study is about Marfan syndrome and does not provide information on the prevalence of Axenfeld-Rieger syndrome.	"{""explanation"": ""The study is about Marfan syndrome and does not provide information on the prevalence of Axenfeld-Rieger syndrome."", ""reference"": ""PMID:37684520"", ""snippet"": ""Marfan syndrome (MFS) is an autosomal dominant condition characterized by aortic aneurysm, skeletal abnormalities, and lens dislocation, and is caused by variants in the FBN1 gene."", ""supports"": ""NO_EVIDENCE""}"
1114	823	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	prevalence	0	evidence	3	PMID:34229749	NO_EVIDENCE		Rhizomelic chondrodysplasia punctata (RCDP) is an inherited ultra-rare disease which results in severely impaired physical and mental development.	The study focuses on Rhizomelic chondrodysplasia punctata and does not provide information on the prevalence of Axenfeld-Rieger syndrome.	"{""explanation"": ""The study focuses on Rhizomelic chondrodysplasia punctata and does not provide information on the prevalence of Axenfeld-Rieger syndrome."", ""reference"": ""PMID:34229749"", ""snippet"": ""Rhizomelic chondrodysplasia punctata (RCDP) is an inherited ultra-rare disease which results in severely impaired physical and mental development."", ""supports"": ""NO_EVIDENCE""}"
1115	823	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	prevalence	0	evidence	4	PMID:29793789	NO_EVIDENCE		Axenfeld-Rieger syndrome.	The title indicates the study is about Axenfeld-Rieger syndrome, but it does not provide specific prevalence data in the general population.	"{""explanation"": ""The title indicates the study is about Axenfeld-Rieger syndrome, but it does not provide specific prevalence data in the general population."", ""reference"": ""PMID:29793789"", ""snippet"": ""Axenfeld-Rieger syndrome."", ""supports"": ""NO_EVIDENCE""}"
1116	823	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	prevalence	0	evidence	5	PMID:28513611	NO_EVIDENCE		Variation in FOXC1 and PITX2 is associated with Axenfeld-Rieger syndrome, characterised by structural defects of the anterior chamber of the eye and a range of systemic features.	The study discusses the genetic associations and clinical features of Axenfeld-Rieger syndrome but does not provide prevalence data in the general population.	"{""explanation"": ""The study discusses the genetic associations and clinical features of Axenfeld-Rieger syndrome but does not provide prevalence data in the general population."", ""reference"": ""PMID:28513611"", ""snippet"": ""Variation in FOXC1 and PITX2 is associated with Axenfeld-Rieger syndrome, characterised by structural defects of the anterior chamber of the eye and a range of systemic features."", ""supports"": ""NO_EVIDENCE""}"
1117	823	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	prevalence	0	evidence	6	PMID:36255854	NO_EVIDENCE		The purpose of this study was to compare the corneal endothelial characteristics in Axenfeld anomaly (AXA), Rieger anomaly (RGA), and Axenfeld-Rieger anomaly/syndrome with age-matched healthy controls.	The study focuses on corneal endothelial characteristics in patients with Axenfeld-Rieger syndrome and does not provide prevalence data in the general population.	"{""explanation"": ""The study focuses on corneal endothelial characteristics in patients with Axenfeld-Rieger syndrome and does not provide prevalence data in the general population."", ""reference"": ""PMID:36255854"", ""snippet"": ""The purpose of this study was to compare the corneal endothelial characteristics in Axenfeld anomaly (AXA), Rieger anomaly (RGA), and Axenfeld-Rieger anomaly/syndrome with age-matched healthy controls."", ""supports"": ""NO_EVIDENCE""}"
1118	823	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	prevalence	0	evidence	7	PMID:32357855	NO_EVIDENCE		The surgical management of glaucoma associated with Axenfeld-Rieger Syndrome (ARS) is poorly described in the literature.	The study discusses the surgical outcomes of glaucoma associated with Axenfeld-Rieger syndrome but does not provide prevalence data in the general population.	"{""explanation"": ""The study discusses the surgical outcomes of glaucoma associated with Axenfeld-Rieger syndrome but does not provide prevalence data in the general population."", ""reference"": ""PMID:32357855"", ""snippet"": ""The surgical management of glaucoma associated with Axenfeld-Rieger Syndrome (ARS) is poorly described in the literature."", ""supports"": ""NO_EVIDENCE""}"
1119	823	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	prevalence	0	evidence	8	PMID:9618168	NO_EVIDENCE		Axenfeld-Rieger syndrome (ARS) and iridogoniodysgenesis syndrome (IGDS) are clinically related autosomal dominant disorders which affect the anterior segment of the eye as well as non-ocular structures.	The study discusses the genetic and clinical relationship between Axenfeld-Rieger syndrome and iridogoniodysgenesis syndrome but does not provide prevalence data in the general population.	"{""explanation"": ""The study discusses the genetic and clinical relationship between Axenfeld-Rieger syndrome and iridogoniodysgenesis syndrome but does not provide prevalence data in the general population."", ""reference"": ""PMID:9618168"", ""snippet"": ""Axenfeld-Rieger syndrome (ARS) and iridogoniodysgenesis syndrome (IGDS) are clinically related autosomal dominant disorders which affect the anterior segment of the eye as well as non-ocular structures."", ""supports"": ""NO_EVIDENCE""}"
1231	947	39	Bacterial meningitis	Bacterial_meningitis.yaml	prevalence	0	evidence	0	PMID:26453240	SUPPORT		Most countries had a yearly invasive NmB incidence of less than 2 per 100,000 people. Within these relatively low incidence rates (compared with common causes of invasive bacterial diseases), substantial variation was detected between countries, with a notably higher incidence in Australia, Europe, North America, and South America. China and India had reports only of sporadic cases, and except for South Africa, sub-Saharan Africa showed a near absence of disease.	The study highlights substantial variation in NmB incidence between countries, which can be influenced by vaccination rates among other factors.	"{""explanation"": ""The study highlights substantial variation in NmB incidence between countries, which can be influenced by vaccination rates among other factors."", ""reference"": ""PMID:26453240"", ""snippet"": ""Most countries had a yearly invasive NmB incidence of less than 2 per 100,000 people. Within these relatively low incidence rates (compared with common causes of invasive bacterial diseases), substantial variation was detected between countries, with a notably higher incidence in Australia, Europe, North America, and South America. China and India had reports only of sporadic cases, and except for South Africa, sub-Saharan Africa showed a near absence of disease."", ""supports"": ""SUPPORT""}"
1232	947	39	Bacterial meningitis	Bacterial_meningitis.yaml	prevalence	0	evidence	1	PMID:34718466	SUPPORT		Meningococcal vaccination is recommended for patients with complement component deficiencies (CDs) in the United States. In this retrospective database study, only 4.6% and 2.2% of patients received MenACWY and MenB vaccination, respectively, within 3 years of CD diagnosis. Thus, meningococcal vaccination rates among patients with CDs need to be improved.	Low vaccination rates among patients with complement component deficiencies in the US suggest that regions with lower vaccination rates may have higher incidences of bacterial meningitis.	"{""explanation"": ""Low vaccination rates among patients with complement component deficiencies in the US suggest that regions with lower vaccination rates may have higher incidences of bacterial meningitis."", ""reference"": ""PMID:34718466"", ""snippet"": ""Meningococcal vaccination is recommended for patients with complement component deficiencies (CDs) in the United States. In this retrospective database study, only 4.6% and 2.2% of patients received MenACWY and MenB vaccination, respectively, within 3 years of CD diagnosis. Thus, meningococcal vaccination rates among patients with CDs need to be improved."", ""supports"": ""SUPPORT""}"
1233	947	39	Bacterial meningitis	Bacterial_meningitis.yaml	prevalence	0	evidence	2	PMID:36117004	SUPPORT		Coverage of the second dose of MenB vaccine at 12 months was >92% in 2017/18, but this may mask inequalities in coverage in particular population groups. MenB vaccination records for children aged six, 12 and 18 months of age from December 2016 to May 2018 were routinely extracted from GP patient management systems every month in England via a web-based platform for national monitoring of vaccine coverage.	This study indicates that while overall vaccination rates may be high, there are inequalities in coverage among different population groups, which can lead to variable rates of bacterial meningitis.	"{""explanation"": ""This study indicates that while overall vaccination rates may be high, there are inequalities in coverage among different population groups, which can lead to variable rates of bacterial meningitis."", ""reference"": ""PMID:36117004"", ""snippet"": ""Coverage of the second dose of MenB vaccine at 12 months was >92% in 2017/18, but this may mask inequalities in coverage in particular population groups. MenB vaccination records for children aged six, 12 and 18 months of age from December 2016 to May 2018 were routinely extracted from GP patient management systems every month in England via a web-based platform for national monitoring of vaccine coverage."", ""supports"": ""SUPPORT""}"
1234	947	39	Bacterial meningitis	Bacterial_meningitis.yaml	prevalence	0	evidence	3	PMID:31640619	SUPPORT		Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis were the most leading pathogens causing bacterial meningitis, accounted for 266(23.44%), 145(12.78%), 95(8.37%) of cases, respectively. Each of the three bacterial species showed a descending trend. The majority of infected subjects are children under five years.	This study shows the prevalence of bacterial meningitis pathogens in Iran before the introduction of vaccines, supporting the idea that vaccination rates impact the incidence of bacterial meningitis.	"{""explanation"": ""This study shows the prevalence of bacterial meningitis pathogens in Iran before the introduction of vaccines, supporting the idea that vaccination rates impact the incidence of bacterial meningitis."", ""reference"": ""PMID:31640619"", ""snippet"": ""Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis were the most leading pathogens causing bacterial meningitis, accounted for 266(23.44%), 145(12.78%), 95(8.37%) of cases, respectively. Each of the three bacterial species showed a descending trend. The majority of infected subjects are children under five years."", ""supports"": ""SUPPORT""}"
1235	947	39	Bacterial meningitis	Bacterial_meningitis.yaml	prevalence	0	evidence	4	PMID:3130424	PARTIAL		During the first pre-vaccination survey, performed during an outbreak of meningococcal disease, the carriage rate was high (16%). The carriage rate remained high during a second survey made 6 months after a vaccination campaign that covered approximately 90% of the study population. A year later very few group A meningococcal carriers were found.	While the vaccination campaign did not immediately reduce the carriage rate, it eventually led to a significant decrease in group A meningococcal carriers, indicating that vaccination can influence meningococcal disease rates over time.	"{""explanation"": ""While the vaccination campaign did not immediately reduce the carriage rate, it eventually led to a significant decrease in group A meningococcal carriers, indicating that vaccination can influence meningococcal disease rates over time."", ""reference"": ""PMID:3130424"", ""snippet"": ""During the first pre-vaccination survey, performed during an outbreak of meningococcal disease, the carriage rate was high (16%). The carriage rate remained high during a second survey made 6 months after a vaccination campaign that covered approximately 90% of the study population. A year later very few group A meningococcal carriers were found."", ""supports"": ""PARTIAL""}"
1236	948	39	Bacterial meningitis	Bacterial_meningitis.yaml	prevalence	1	evidence	0	PMID:16342836	SUPPORT		Serogroup B accounts for the highest incidence of disease in young infants but is not contained in any vaccine licensed in the United States.	The abstract indicates that young infants have the highest incidence of meningococcal disease caused by serogroup B, supporting the statement that infants and young children are at higher risk, particularly if not vaccinated.	"{""explanation"": ""The abstract indicates that young infants have the highest incidence of meningococcal disease caused by serogroup B, supporting the statement that infants and young children are at higher risk, particularly if not vaccinated."", ""reference"": ""PMID:16342836"", ""snippet"": ""Serogroup B accounts for the highest incidence of disease in young infants but is not contained in any vaccine licensed in the United States."", ""supports"": ""SUPPORT""}"
1237	948	39	Bacterial meningitis	Bacterial_meningitis.yaml	prevalence	1	evidence	1	PMID:28301990	SUPPORT		We describe a number of risk factors; including socioeconomic factors, age, genetic variation of the host and underlying medical conditions associated with increased susceptibility to invasive bacterial infections in both children and adults.	The study identifies age as a risk factor for bacterial meningitis, supporting the statement that infants and young children are at higher risk.	"{""explanation"": ""The study identifies age as a risk factor for bacterial meningitis, supporting the statement that infants and young children are at higher risk."", ""reference"": ""PMID:28301990"", ""snippet"": ""We describe a number of risk factors; including socioeconomic factors, age, genetic variation of the host and underlying medical conditions associated with increased susceptibility to invasive bacterial infections in both children and adults."", ""supports"": ""SUPPORT""}"
1238	948	39	Bacterial meningitis	Bacterial_meningitis.yaml	prevalence	1	evidence	2	PMID:18820360	SUPPORT		Our data are the first minimal estimate of the incidence of Hib meningitis for Indian children. The observed incidence data are similar to European reports before Hib vaccine use, suggest substantial disease before 24 months of age, and provide data useful for policy regarding Hib immunization.	The study provides incidence data for Hib meningitis, showing substantial disease in children before 24 months of age, supporting the statement that infants and young children are at higher risk if not vaccinated.	"{""explanation"": ""The study provides incidence data for Hib meningitis, showing substantial disease in children before 24 months of age, supporting the statement that infants and young children are at higher risk if not vaccinated."", ""reference"": ""PMID:18820360"", ""snippet"": ""Our data are the first minimal estimate of the incidence of Hib meningitis for Indian children. The observed incidence data are similar to European reports before Hib vaccine use, suggest substantial disease before 24 months of age, and provide data useful for policy regarding Hib immunization."", ""supports"": ""SUPPORT""}"
1239	948	39	Bacterial meningitis	Bacterial_meningitis.yaml	prevalence	1	evidence	3	PMID:36117004	SUPPORT		In England, the Meningitis B (MenB) vaccine is scheduled at eight and 16 weeks with a booster dose at one year of age and protects children against invasive bacterial meningococcal disease caused by Neisseria meningitidis serogroup B.	The abstract mentions the vaccination schedule for MenB and its role in protecting children against invasive bacterial meningococcal disease, supporting the statement that infants and young children are at higher risk if not vaccinated.	"{""explanation"": ""The abstract mentions the vaccination schedule for MenB and its role in protecting children against invasive bacterial meningococcal disease, supporting the statement that infants and young children are at higher risk if not vaccinated."", ""reference"": ""PMID:36117004"", ""snippet"": ""In England, the Meningitis B (MenB) vaccine is scheduled at eight and 16 weeks with a booster dose at one year of age and protects children against invasive bacterial meningococcal disease caused by Neisseria meningitidis serogroup B."", ""supports"": ""SUPPORT""}"
1240	948	39	Bacterial meningitis	Bacterial_meningitis.yaml	prevalence	1	evidence	4	PMID:34469553	SUPPORT		We investigated the characteristics of etiological agents causing bacterial meningitis in children <5 years in the years pre- (2010-2012) and post- (2014-2019) 10-valent pneumococcal conjugate vaccine (PCV10) introduction in Zambia.	The study investigates bacterial meningitis in children under 5 years, supporting the statement that infants and young children are at higher risk, particularly if not vaccinated.	"{""explanation"": ""The study investigates bacterial meningitis in children under 5 years, supporting the statement that infants and young children are at higher risk, particularly if not vaccinated."", ""reference"": ""PMID:34469553"", ""snippet"": ""We investigated the characteristics of etiological agents causing bacterial meningitis in children <5 years in the years pre- (2010-2012) and post- (2014-2019) 10-valent pneumococcal conjugate vaccine (PCV10) introduction in Zambia."", ""supports"": ""SUPPORT""}"
1241	949	39	Bacterial meningitis	Bacterial_meningitis.yaml	prevalence	2	evidence	0	PMID:6466018	SUPPORT		Meningitis in the elderly is likely to be bacterial and to cause greater morbidity and mortality.	The study indicates that elderly patients have a high incidence of bacterial meningitis with serious complications and high mortality, which supports the statement that the elderly population is at increased risk due to a weakened immune system.	"{""explanation"": ""The study indicates that elderly patients have a high incidence of bacterial meningitis with serious complications and high mortality, which supports the statement that the elderly population is at increased risk due to a weakened immune system."", ""reference"": ""PMID:6466018"", ""snippet"": ""Meningitis in the elderly is likely to be bacterial and to cause greater morbidity and mortality."", ""supports"": ""SUPPORT""}"
1242	949	39	Bacterial meningitis	Bacterial_meningitis.yaml	prevalence	2	evidence	1	PMID:6372470	SUPPORT		Certain host factors increase the risk of acquiring meningitis and include: age (increased at extremes of life)...	The reference mentions age as a risk factor for bacterial meningitis, which supports the statement that the elderly are at increased risk.	"{""explanation"": ""The reference mentions age as a risk factor for bacterial meningitis, which supports the statement that the elderly are at increased risk."", ""reference"": ""PMID:6372470"", ""snippet"": ""Certain host factors increase the risk of acquiring meningitis and include: age (increased at extremes of life)..."", ""supports"": ""SUPPORT""}"
1243	950	39	Bacterial meningitis	Bacterial_meningitis.yaml	prevalence	3	evidence	0	PMID:1610138	SUPPORT		Bacterial meningitis in the immunocompromised host.	The title of the reference directly indicates a focus on bacterial meningitis in immunocompromised individuals, suggesting they are more susceptible.	"{""explanation"": ""The title of the reference directly indicates a focus on bacterial meningitis in immunocompromised individuals, suggesting they are more susceptible."", ""reference"": ""PMID:1610138"", ""snippet"": ""Bacterial meningitis in the immunocompromised host."", ""supports"": ""SUPPORT""}"
1244	950	39	Bacterial meningitis	Bacterial_meningitis.yaml	prevalence	3	evidence	1	PMID:31830496	SUPPORT		GBS meningitis in adults mainly occurs in those with underlying conditions such as immunocompromised state, CSF leakage, and endocarditis.	The study indicates that GBS meningitis in adults is more common in those with an immunocompromised state, supporting the statement.	"{""explanation"": ""The study indicates that GBS meningitis in adults is more common in those with an immunocompromised state, supporting the statement."", ""reference"": ""PMID:31830496"", ""snippet"": ""GBS meningitis in adults mainly occurs in those with underlying conditions such as immunocompromised state, CSF leakage, and endocarditis."", ""supports"": ""SUPPORT""}"
1245	950	39	Bacterial meningitis	Bacterial_meningitis.yaml	prevalence	3	evidence	2	PMID:36472590	SUPPORT		In adults, risk factors for bacterial meningitis include older age and immunosuppressive conditions.	The abstract mentions immunosuppressive conditions as a risk factor for bacterial meningitis, supporting the statement.	"{""explanation"": ""The abstract mentions immunosuppressive conditions as a risk factor for bacterial meningitis, supporting the statement."", ""reference"": ""PMID:36472590"", ""snippet"": ""In adults, risk factors for bacterial meningitis include older age and immunosuppressive conditions."", ""supports"": ""SUPPORT""}"
1356	995	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	prevalence	0	evidence	0	PMID:22109794	PARTIAL		The prevalence of BBS has been estimated in different populations, ranging from 1 in 160,000 in European populations to 1 in 13,000 in Bedouins from Kuwait.	The prevalence range provided in the literature is specific to certain populations, but does suggest that globally, the prevalence could fall within the stated range percentage (0.00001-0.00003).	"{""explanation"": ""The prevalence range provided in the literature is specific to certain populations, but does suggest that globally, the prevalence could fall within the stated range percentage (0.00001-0.00003)."", ""reference"": ""PMID:22109794"", ""snippet"": ""The prevalence of BBS has been estimated in different populations, ranging from 1 in 160,000 in European populations to 1 in 13,000 in Bedouins from Kuwait."", ""supports"": ""PARTIAL""}"
1357	995	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	prevalence	0	evidence	1	PMID:37137806	NO_EVIDENCE		AIMS: We described the updated global IBD epidemiology results based on the 2019 Global Burden of Diseases, Injuries, and Risk Factors Study (GBD).	This paper deals with inflammatory bowel disease (IBD) and provides no direct evidence about the global prevalence of Bardet-Biedl Syndrome.	"{""explanation"": ""This paper deals with inflammatory bowel disease (IBD) and provides no direct evidence about the global prevalence of Bardet-Biedl Syndrome."", ""reference"": ""PMID:37137806"", ""snippet"": ""AIMS: We described the updated global IBD epidemiology results based on the 2019 Global Burden of Diseases, Injuries, and Risk Factors Study (GBD)."", ""supports"": ""NO_EVIDENCE""}"
1470	1162	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	prevalence	0	evidence	0	PMID:23101639	SUPPORT	HUMAN_CLINICAL	Domestic hypersensitivity pneumonitis (HP) cases are relatively widespread, with an overall annual incidence of approximately 1/100,000 reported in a British study covering several million patients.	The review reports a UK annual incidence estimate that can be used as a population-level rate for HP including bird fancier's lung.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The review reports a UK annual incidence estimate that can be used as a population-level rate for HP including bird fancier's lung."", ""reference"": ""PMID:23101639"", ""snippet"": ""Domestic hypersensitivity pneumonitis (HP) cases are relatively widespread, with an overall annual incidence of approximately 1/100,000 reported in a British study covering several million patients."", ""supports"": ""SUPPORT""}"
1707	1446	61	Cholera	Cholera.yaml	prevalence	0	evidence	0	PMID:22461716	SUPPORT		The percentages of the population in each country that lacked access to improved sanitation were used to compute the populations at risk for cholera.	The study links the risk of cholera to the lack of improved sanitation, supporting the statement that cholera prevalence is higher in regions with poor sanitation.	"{""explanation"": ""The study links the risk of cholera to the lack of improved sanitation, supporting the statement that cholera prevalence is higher in regions with poor sanitation."", ""reference"": ""PMID:22461716"", ""snippet"": ""The percentages of the population in each country that lacked access to improved sanitation were used to compute the populations at risk for cholera."", ""supports"": ""SUPPORT""}"
1708	1446	61	Cholera	Cholera.yaml	prevalence	0	evidence	1	PMID:36639850	SUPPORT		Cholera transmission is associated with several socio-economic and environmental factors, each associated variable is suggested to have at least one mediating mechanism.	The review highlights the influence of socio-economic factors like sanitation on cholera transmission, supporting the statement.	"{""explanation"": ""The review highlights the influence of socio-economic factors like sanitation on cholera transmission, supporting the statement."", ""reference"": ""PMID:36639850"", ""snippet"": ""Cholera transmission is associated with several socio-economic and environmental factors, each associated variable is suggested to have at least one mediating mechanism."", ""supports"": ""SUPPORT""}"
1709	1447	61	Cholera	Cholera.yaml	prevalence	1	evidence	0	PMID:34550374	SUPPORT		in many developing nations such as India, cholera disease is endemic.	The reference clearly indicates that cholera is endemic in India, a part of South Asia.	"{""explanation"": ""The reference clearly indicates that cholera is endemic in India, a part of South Asia."", ""reference"": ""PMID:34550374"", ""snippet"": ""in many developing nations such as India, cholera disease is endemic."", ""supports"": ""SUPPORT""}"
1710	1447	61	Cholera	Cholera.yaml	prevalence	1	evidence	1	PMID:34633491	SUPPORT		Cholera has been endemic to the Ganges Delta for centuries. Although the causative agent, Vibrio cholerae, is autochthonous to coastal and brackish water, cholera occurs continually in Dhaka, the inland capital city of Bangladesh which is surrounded by fresh water.	The reference indicates that cholera is endemic in the Ganges Delta, which is part of South Asia, and it specifically mentions Dhaka, Bangladesh.	"{""explanation"": ""The reference indicates that cholera is endemic in the Ganges Delta, which is part of South Asia, and it specifically mentions Dhaka, Bangladesh."", ""reference"": ""PMID:34633491"", ""snippet"": ""Cholera has been endemic to the Ganges Delta for centuries. Although the causative agent, Vibrio cholerae, is autochthonous to coastal and brackish water, cholera occurs continually in Dhaka, the inland capital city of Bangladesh which is surrounded by fresh water."", ""supports"": ""SUPPORT""}"
1711	1447	61	Cholera	Cholera.yaml	prevalence	1	evidence	2	PMID:34453539	SUPPORT		In 2014, Bangladesh established a nationwide, facility-based cholera surveillance system for Vibrio cholerae infection... The cholera surveillance system in Bangladesh has the ability to monitor progress towards cholera elimination goals.	The reference mentions the ongoing surveillance and control measures in Bangladesh, implicitly supporting the idea of cholera being endemic and prevalent in the region.	"{""explanation"": ""The reference mentions the ongoing surveillance and control measures in Bangladesh, implicitly supporting the idea of cholera being endemic and prevalent in the region."", ""reference"": ""PMID:34453539"", ""snippet"": ""In 2014, Bangladesh established a nationwide, facility-based cholera surveillance system for Vibrio cholerae infection... The cholera surveillance system in Bangladesh has the ability to monitor progress towards cholera elimination goals."", ""supports"": ""SUPPORT""}"
1712	1447	61	Cholera	Cholera.yaml	prevalence	1	evidence	3	PMID:20562706	SUPPORT		The mechanisms underlying the seasonality of cholera are still not fully understood, despite long-standing recognition of clear bimodal seasonality in Bangladesh.	This reference supports the statement by acknowledging the long-standing endemicity and seasonal patterns of cholera in Bangladesh.	"{""explanation"": ""This reference supports the statement by acknowledging the long-standing endemicity and seasonal patterns of cholera in Bangladesh."", ""reference"": ""PMID:20562706"", ""snippet"": ""The mechanisms underlying the seasonality of cholera are still not fully understood, despite long-standing recognition of clear bimodal seasonality in Bangladesh."", ""supports"": ""SUPPORT""}"
1713	1448	61	Cholera	Cholera.yaml	prevalence	2	evidence	0	PMID:24827501	PARTIAL		More than 40 years after its resurgence in Africa in 1970, cholera remains a grave public health problem, characterized by large disease burden, frequent outbreaks, persistent endemicity, and high CFRs, particularly in the region of the central African Great Lakes which might act as reservoirs for cholera	The reference supports that cholera is a persistent endemic problem in parts of Africa (e.g., Central African Great Lakes) and accounts for a significant portion of global cases and deaths. However, it does not specify the exact percentage of the population in Africa that is affected.	"{""explanation"": ""The reference supports that cholera is a persistent endemic problem in parts of Africa (e.g., Central African Great Lakes) and accounts for a significant portion of global cases and deaths. However, it does not specify the exact percentage of the population in Africa that is affected."", ""reference"": ""PMID:24827501"", ""snippet"": ""More than 40 years after its resurgence in Africa in 1970, cholera remains a grave public health problem, characterized by large disease burden, frequent outbreaks, persistent endemicity, and high CFRs, particularly in the region of the central African Great Lakes which might act as reservoirs for cholera"", ""supports"": ""PARTIAL""}"
1714	1449	61	Cholera	Cholera.yaml	prevalence	3	evidence	0	PMID:37610182	SUPPORT		In Haiti in 2017, the prevalence of serum vibriocidal antibody titers against Vibrio cholerae serogroup O1 among adults was 12.4% in Cerca-la-Source and 9.54% in Mirebalais.	The data indicates a high prevalence of recent infection, suggesting cholera is prevalent among the endemic population in Haiti.	"{""explanation"": ""The data indicates a high prevalence of recent infection, suggesting cholera is prevalent among the endemic population in Haiti."", ""reference"": ""PMID:37610182"", ""snippet"": ""In Haiti in 2017, the prevalence of serum vibriocidal antibody titers against Vibrio cholerae serogroup O1 among adults was 12.4% in Cerca-la-Source and 9.54% in Mirebalais."", ""supports"": ""SUPPORT""}"
1715	1449	61	Cholera	Cholera.yaml	prevalence	3	evidence	1	PMID:23301694	SUPPORT		Within days after detection, the Ministry of Public Health and Population established a National Cholera Surveillance System (NCSS)... Through October 20, 2012, the public health ministry reported 604,634 cases of infection, 329,697 hospitalizations, and 7436 deaths from cholera.	The large number of reported cases indicates a significant prevalence of cholera in Haiti.	"{""explanation"": ""The large number of reported cases indicates a significant prevalence of cholera in Haiti."", ""reference"": ""PMID:23301694"", ""snippet"": ""Within days after detection, the Ministry of Public Health and Population established a National Cholera Surveillance System (NCSS)... Through October 20, 2012, the public health ministry reported 604,634 cases of infection, 329,697 hospitalizations, and 7436 deaths from cholera."", ""supports"": ""SUPPORT""}"
1716	1449	61	Cholera	Cholera.yaml	prevalence	3	evidence	2	PMID:33350917	SUPPORT		Centre Department, Haiti, was the origin of a major cholera epidemic during 2010-2019.	The outbreak in Haiti's Centre Department signifies a high prevalence of cholera within the endemic population over a considerable period.	"{""explanation"": ""The outbreak in Haiti's Centre Department signifies a high prevalence of cholera within the endemic population over a considerable period."", ""reference"": ""PMID:33350917"", ""snippet"": ""Centre Department, Haiti, was the origin of a major cholera epidemic during 2010-2019."", ""supports"": ""SUPPORT""}"
1717	1449	61	Cholera	Cholera.yaml	prevalence	3	evidence	3	PMID:35259956	SUPPORT		We also show that, in our model, effective reproduction numbers and epidemicity indices are explicitly related. Therefore, providing an upper bound to the effective reproduction number (significantly lower than the unit threshold) warrants negative epidemicity and, in turn, a rapidly fading outbreak preventing coalescence of sparse local sub-threshold flare-ups.	The discussion on controlling the cholera spread through negative epidemicity indicates efforts to manage the disease prevalence.	"{""explanation"": ""The discussion on controlling the cholera spread through negative epidemicity indicates efforts to manage the disease prevalence."", ""reference"": ""PMID:35259956"", ""snippet"": ""We also show that, in our model, effective reproduction numbers and epidemicity indices are explicitly related. Therefore, providing an upper bound to the effective reproduction number (significantly lower than the unit threshold) warrants negative epidemicity and, in turn, a rapidly fading outbreak preventing coalescence of sparse local sub-threshold flare-ups."", ""supports"": ""SUPPORT""}"
1718	1449	61	Cholera	Cholera.yaml	prevalence	3	evidence	4	PMID:37735743	SUPPORT		The 2010 cholera epidemic in Haiti was thought to have ended in 2019, and the Prime Minister of Haiti declared the country cholera-free in February 2022. On September 25, 2022, cholera cases were again identified in Port-au-Prince.	Re-emergence of cases suggests ongoing cholera prevalence even after being declared cholera-free.	"{""explanation"": ""Re-emergence of cases suggests ongoing cholera prevalence even after being declared cholera-free."", ""reference"": ""PMID:37735743"", ""snippet"": ""The 2010 cholera epidemic in Haiti was thought to have ended in 2019, and the Prime Minister of Haiti declared the country cholera-free in February 2022. On September 25, 2022, cholera cases were again identified in Port-au-Prince."", ""supports"": ""SUPPORT""}"
1874	1603	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	prevalence	0	evidence	0	PMID:35261410	NO_EVIDENCE		The estimated pooled prevalence of COPD was 11.1% (95% confidence interval, CI: 7.4-14.8%), using the Global Initiative for Chronic Obstructive Lung Disease fixed criteria and 8.0% (95% CI: 5.6-10.4%) using the lower limit of normal criteria.	The study provides prevalence data for specific regions (e.g., South Asia) but does not mention a global prevalence rate of 11.7%.	"{""explanation"": ""The study provides prevalence data for specific regions (e.g., South Asia) but does not mention a global prevalence rate of 11.7%."", ""reference"": ""PMID:35261410"", ""snippet"": ""The estimated pooled prevalence of COPD was 11.1% (95% confidence interval, CI: 7.4-14.8%), using the Global Initiative for Chronic Obstructive Lung Disease fixed criteria and 8.0% (95% CI: 5.6-10.4%) using the lower limit of normal criteria."", ""supports"": ""NO_EVIDENCE""}"
1875	1603	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	prevalence	0	evidence	1	PMID:37461046	NO_EVIDENCE		Though disease burden of silicosis has been on a decline in general from 1990 to 2019, which shows a promising prospect but cannot be ignored.	This study focuses on the global incidence, prevalence, and disease burden of silicosis, not COPD.	"{""explanation"": ""This study focuses on the global incidence, prevalence, and disease burden of silicosis, not COPD."", ""reference"": ""PMID:37461046"", ""snippet"": ""Though disease burden of silicosis has been on a decline in general from 1990 to 2019, which shows a promising prospect but cannot be ignored."", ""supports"": ""NO_EVIDENCE""}"
2107	1851	77	Crohn Disease	Crohn_Disease.yaml	prevalence	0	evidence	0	PMID:37137806	WRONG_STATEMENT		The crude prevalence of IBD increased by 47% in 2019 globally.	The available literature does not provide specific data on the percentage prevalence of Crohn's Disease alone globally; it talks about the prevalence of IBD as a whole.	"{""explanation"": ""The available literature does not provide specific data on the percentage prevalence of Crohn's Disease alone globally; it talks about the prevalence of IBD as a whole."", ""reference"": ""PMID:37137806"", ""snippet"": ""The crude prevalence of IBD increased by 47% in 2019 globally."", ""supports"": ""WRONG_STATEMENT""}"
2108	1851	77	Crohn Disease	Crohn_Disease.yaml	prevalence	0	evidence	1	PMID:35930087	NO_EVIDENCE		This prospective, observational registry study was conducted at 19 tertiary centers in Japan. Patients newly diagnosed with Crohn''s disease after June 2016 (age >/= 16 years at informed consent) were enrolled between December 17, 2018 and June 30, 2020.	This study focuses on the prevalence and characteristics of Crohn's Disease specifically in Japan, not globally.	"{""explanation"": ""This study focuses on the prevalence and characteristics of Crohn's Disease specifically in Japan, not globally."", ""reference"": ""PMID:35930087"", ""snippet"": ""This prospective, observational registry study was conducted at 19 tertiary centers in Japan. Patients newly diagnosed with Crohn''s disease after June 2016 (age >/= 16 years at informed consent) were enrolled between December 17, 2018 and June 30, 2020."", ""supports"": ""NO_EVIDENCE""}"
2399	2265	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	prevalence	0	evidence	0	PMID:31002071	SUPPORT		Our results suggest a serologic prevalence of 2%-3.5% in the Republic of the Congo and the Democratic Republic of the Congo, which have reported outbreaks of infection with EBOV. In addition we detected a seroprevalence of 1.3% in southern Cameroon, which indicated a low risk for exposure in this region.	The study shows variation in serologic prevalence of EBOV in different regions of Central Africa, which supports the statement that EVD prevalence is outbreak-dependent and varies by region in Central Africa.	"{""explanation"": ""The study shows variation in serologic prevalence of EBOV in different regions of Central Africa, which supports the statement that EVD prevalence is outbreak-dependent and varies by region in Central Africa."", ""reference"": ""PMID:31002071"", ""snippet"": ""Our results suggest a serologic prevalence of 2%-3.5% in the Republic of the Congo and the Democratic Republic of the Congo, which have reported outbreaks of infection with EBOV. In addition we detected a seroprevalence of 1.3% in southern Cameroon, which indicated a low risk for exposure in this region."", ""supports"": ""SUPPORT""}"
2400	2265	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	prevalence	0	evidence	1	PMID:34077889	SUPPORT		The most EVD-affected countries were the Democratic Republic of Congo with five outbreaks and a pooled CFR of 65% (95% CI: 59-71%), followed by Uganda with three outbreaks and CFR of 83% (95% CI: 60-99%).	This meta-analysis shows varying case fatality rates and the prevalence of EVD outbreaks in Central Africa, supporting the statement that the prevalence is outbreak-dependent.	"{""explanation"": ""This meta-analysis shows varying case fatality rates and the prevalence of EVD outbreaks in Central Africa, supporting the statement that the prevalence is outbreak-dependent."", ""reference"": ""PMID:34077889"", ""snippet"": ""The most EVD-affected countries were the Democratic Republic of Congo with five outbreaks and a pooled CFR of 65% (95% CI: 59-71%), followed by Uganda with three outbreaks and CFR of 83% (95% CI: 60-99%)."", ""supports"": ""SUPPORT""}"
2496	2309	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	prevalence	0	evidence	0	PMID:28077691	PARTIAL		The cohort held 1427 unique persons with EDS, giving a national prevalence of 0.02%.	The study confirms a prevalence of 0.02%, but this data is specific to the Danish population. The statement claims this prevalence on a global scale, which the provided literature does not support.	"{""explanation"": ""The study confirms a prevalence of 0.02%, but this data is specific to the Danish population. The statement claims this prevalence on a global scale, which the provided literature does not support."", ""reference"": ""PMID:28077691"", ""snippet"": ""The cohort held 1427 unique persons with EDS, giving a national prevalence of 0.02%."", ""supports"": ""PARTIAL""}"
2552	2333	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	prevalence	0	evidence	0	PMID:20847697	PARTIAL		It is currently estimated that approximately 50% of patients with a clinical diagnosis of classic Ehlers-Danlos syndrome harbor mutations in the COL5A1 and the COL5A2 gene.	This reference indicates that COL5A1-related EDS is a subset of classic EDS, making up about 50% of classic EDS cases. However, it does not provide specific global prevalence rates of COL5A1-related EDS.	"{""explanation"": ""This reference indicates that COL5A1-related EDS is a subset of classic EDS, making up about 50% of classic EDS cases. However, it does not provide specific global prevalence rates of COL5A1-related EDS."", ""reference"": ""PMID:20847697"", ""snippet"": ""It is currently estimated that approximately 50% of patients with a clinical diagnosis of classic Ehlers-Danlos syndrome harbor mutations in the COL5A1 and the COL5A2 gene."", ""supports"": ""PARTIAL""}"
2663	2544	111	FICUS syndrome	FICUS_syndrome.yaml	prevalence	0	evidence	0	PMID:35795400	SUPPORT		Overall PICS-F occurred in 33%.	This study reports overall PICS-F occurrence among ICU family members of COVID-19 patients.	"{""explanation"": ""This study reports overall PICS-F occurrence among ICU family members of COVID-19 patients."", ""reference"": ""PMID:35795400"", ""snippet"": ""Overall PICS-F occurred in 33%."", ""supports"": ""SUPPORT""}"
2664	2545	111	FICUS syndrome	FICUS_syndrome.yaml	prevalence	1	evidence	0	PMID:29277171	SUPPORT		We found a significant prevalence of anxiety (45.8%), depression (25%), and PTSD (11.1%) symptoms among FDMs over the course of the study.	This provides symptom prevalence estimates in family decision-makers during and after ICU admission.	"{""explanation"": ""This provides symptom prevalence estimates in family decision-makers during and after ICU admission."", ""reference"": ""PMID:29277171"", ""snippet"": ""We found a significant prevalence of anxiety (45.8%), depression (25%), and PTSD (11.1%) symptoms among FDMs over the course of the study."", ""supports"": ""SUPPORT""}"
2751	2636	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	prevalence	0	evidence	0	PMID:32608308	REFUTE		The predominant ethnicities were Turkish (41.8%), Lebanese (15.8%), Syrian (6.5%), South-West Asian (7.9%), and South-East Asian (3.0%).	The prevalence in Mediterranean populations, such as Turkish (41.8%) and Lebanese (15.8%), is much higher than 0.1-0.2%.	"{""explanation"": ""The prevalence in Mediterranean populations, such as Turkish (41.8%) and Lebanese (15.8%), is much higher than 0.1-0.2%."", ""reference"": ""PMID:32608308"", ""snippet"": ""The predominant ethnicities were Turkish (41.8%), Lebanese (15.8%), Syrian (6.5%), South-West Asian (7.9%), and South-East Asian (3.0%)."", ""supports"": ""REFUTE""}"
2752	2636	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	prevalence	0	evidence	1	PMID:11053071	NO_EVIDENCE		Phenotype II is uncommon among the relatives of patients with FMF and amyloidosis.	This study does not provide direct evidence on the overall prevalence of FMF in the Mediterranean populations.	"{""explanation"": ""This study does not provide direct evidence on the overall prevalence of FMF in the Mediterranean populations."", ""reference"": ""PMID:11053071"", ""snippet"": ""Phenotype II is uncommon among the relatives of patients with FMF and amyloidosis."", ""supports"": ""NO_EVIDENCE""}"
2753	2636	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	prevalence	0	evidence	2	PMID:3306755	REFUTE		Recurrent hereditary polyserositis (RHP) or familial Mediterranean fever (FMF) is a chronic inherited illness of obscure aetiology... and predominantly affects Sephardic Jews, Arabs, Turks and Armenians.	The article suggests that FMF predominantly affects specific Mediterranean populations, implying a higher prevalence than 0.1-0.2% among these groups.	"{""explanation"": ""The article suggests that FMF predominantly affects specific Mediterranean populations, implying a higher prevalence than 0.1-0.2% among these groups."", ""reference"": ""PMID:3306755"", ""snippet"": ""Recurrent hereditary polyserositis (RHP) or familial Mediterranean fever (FMF) is a chronic inherited illness of obscure aetiology... and predominantly affects Sephardic Jews, Arabs, Turks and Armenians."", ""supports"": ""REFUTE""}"
2754	2636	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	prevalence	0	evidence	3	PMID:34363075	NO_EVIDENCE		The aim of this study was to determine the prevalence of FMF in children with cryptogenic cirrhosis and it was found to be high, to add FMF among the etiological causes of cirrhosis	The study focused on children with cryptogenic cirrhosis and does not provide general prevalence data for Mediterranean populations.	"{""explanation"": ""The study focused on children with cryptogenic cirrhosis and does not provide general prevalence data for Mediterranean populations."", ""reference"": ""PMID:34363075"", ""snippet"": ""The aim of this study was to determine the prevalence of FMF in children with cryptogenic cirrhosis and it was found to be high, to add FMF among the etiological causes of cirrhosis"", ""supports"": ""NO_EVIDENCE""}"
3202	3168	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	prevalence	0	evidence	0	PMID:19233695	WRONG_STATEMENT		Glucose-6-phosphate deficiency is the most prevalent enzyme deficiency, with an estimated 400 million people affected worldwide.	The literature indicates that G6PD deficiency is the most common enzyme deficiency affecting approximately 400 million people. This would suggest a global prevalence rate higher than 4.9%.	"{""explanation"": ""The literature indicates that G6PD deficiency is the most common enzyme deficiency affecting approximately 400 million people. This would suggest a global prevalence rate higher than 4.9%."", ""reference"": ""PMID:19233695"", ""snippet"": ""Glucose-6-phosphate deficiency is the most prevalent enzyme deficiency, with an estimated 400 million people affected worldwide."", ""supports"": ""WRONG_STATEMENT""}"
3203	3168	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	prevalence	0	evidence	1	PMID:34699526	NO_EVIDENCE		Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is the most common enzymopathy globally	The abstract does not provide specific global prevalence percentages but suggests the condition is very common worldwide.	"{""explanation"": ""The abstract does not provide specific global prevalence percentages but suggests the condition is very common worldwide."", ""reference"": ""PMID:34699526"", ""snippet"": ""Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is the most common enzymopathy globally"", ""supports"": ""NO_EVIDENCE""}"
3204	3168	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	prevalence	0	evidence	2	PMID:31833391	NO_EVIDENCE		G6PD deficiency was reported in India more than 50 years ago and the prevalence rate varies from 5.7% to 27.9% in different caste and tribal groups.	This indicates a higher prevalence in specific populations but does not provide a global percentage.	"{""explanation"": ""This indicates a higher prevalence in specific populations but does not provide a global percentage."", ""reference"": ""PMID:31833391"", ""snippet"": ""G6PD deficiency was reported in India more than 50 years ago and the prevalence rate varies from 5.7% to 27.9% in different caste and tribal groups."", ""supports"": ""NO_EVIDENCE""}"
3205	3168	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	prevalence	0	evidence	3	PMID:29739104	NO_EVIDENCE		This study analyzed the prevalence of G6PD deficiency in Sichuan, China.	The study focuses on a specific region and does not provide global prevalence data.	"{""explanation"": ""The study focuses on a specific region and does not provide global prevalence data."", ""reference"": ""PMID:29739104"", ""snippet"": ""This study analyzed the prevalence of G6PD deficiency in Sichuan, China."", ""supports"": ""NO_EVIDENCE""}"
3206	3169	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	prevalence	1	evidence	0	PMID:20732351	PARTIAL		Rates were higher among African Americans (68/699; 9.7%)	The study reported a prevalence rate of 9.7% for G6PD deficiency among African Americans, which is close but not exactly 10%.	"{""explanation"": ""The study reported a prevalence rate of 9.7% for G6PD deficiency among African Americans, which is close but not exactly 10%."", ""reference"": ""PMID:20732351"", ""snippet"": ""Rates were higher among African Americans (68/699; 9.7%)"", ""supports"": ""PARTIAL""}"
3207	3170	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	prevalence	2	evidence	0	PMID:33560519	PARTIAL		The incidence of G6PD deficiency appeared to be severely underestimated.	Specific prevalence range not provided, but implies awareness is low, suggesting there could be underreported cases.	"{""explanation"": ""Specific prevalence range not provided, but implies awareness is low, suggesting there could be underreported cases."", ""reference"": ""PMID:33560519"", ""snippet"": ""The incidence of G6PD deficiency appeared to be severely underestimated."", ""supports"": ""PARTIAL""}"
3208	3170	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	prevalence	2	evidence	1	PMID:27853304	PARTIAL		Of the 23 missense mutations, p.S188F, p.I48T, p.N126D, and p.V68M, were identified as the most common mutations among Arab populations	Discusses common mutations in Middle East but does not provide specific prevalence percentages.	"{""explanation"": ""Discusses common mutations in Middle East but does not provide specific prevalence percentages."", ""reference"": ""PMID:27853304"", ""snippet"": ""Of the 23 missense mutations, p.S188F, p.I48T, p.N126D, and p.V68M, were identified as the most common mutations among Arab populations"", ""supports"": ""PARTIAL""}"
3240	3195	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	prevalence	0	evidence	0	PMID:19032739	SUPPORT		The estimated prevalence varies from 1/57,000 to 1/256,000, with a male-to-female ratio of 1:1.	Documents prevalence estimates from Orphanet review.	"{""explanation"": ""Documents prevalence estimates from Orphanet review."", ""reference"": ""PMID:19032739"", ""snippet"": ""The estimated prevalence varies from 1/57,000 to 1/256,000, with a male-to-female ratio of 1:1."", ""supports"": ""SUPPORT""}"
3372	3298	137	Graves' Disease	Graves_Disease.yaml	prevalence	0	evidence	0	PMID:34122333	PARTIAL		After two decades of USI, the prevalence of overt hyperthyroidism (OH), Graves'' disease (GD), severe subclinical hyperthyroidism (severe SCH), and mild subclinical hyperthyroidism (mild SCH) in mainland China was 0.78%, 0.53%, 0.22%, and 0.22%, respectively.	The prevalence of Graves' Disease in mainland China is reported as 0.53%, which falls within the 0.5-1% range. However, this data is specific to mainland China and may not represent a global prevalence.	"{""explanation"": ""The prevalence of Graves' Disease in mainland China is reported as 0.53%, which falls within the 0.5-1% range. However, this data is specific to mainland China and may not represent a global prevalence."", ""reference"": ""PMID:34122333"", ""snippet"": ""After two decades of USI, the prevalence of overt hyperthyroidism (OH), Graves'' disease (GD), severe subclinical hyperthyroidism (severe SCH), and mild subclinical hyperthyroidism (mild SCH) in mainland China was 0.78%, 0.53%, 0.22%, and 0.22%, respectively."", ""supports"": ""PARTIAL""}"
3595	3604	151	Hepatitis B	Hepatitis_B.yaml	prevalence	0	evidence	0	PMID:26231459	PARTIAL		HBsAg seroprevalence was 3.61% (95% CI 3.61-3.61) worldwide.	The statement claims a global prevalence of 3.5%, while the literature states it is 3.61%. The difference is minor, but it is not an exact match.	"{""explanation"": ""The statement claims a global prevalence of 3.5%, while the literature states it is 3.61%. The difference is minor, but it is not an exact match."", ""reference"": ""PMID:26231459"", ""snippet"": ""HBsAg seroprevalence was 3.61% (95% CI 3.61-3.61) worldwide."", ""supports"": ""PARTIAL""}"
3729	3734	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	prevalence	0	evidence	0	PMID:25066220	REFUTE		The total prevalence was 1.09 (95% confidence interval, 1.03-1.15) per 10,000 births.	The prevalence of Hirschsprung's disease is reported to be approximately 1.09 per 10,000 births, which translates to 0.0109%. This is higher than the stated range of 0.0001-0.001%.	"{""explanation"": ""The prevalence of Hirschsprung's disease is reported to be approximately 1.09 per 10,000 births, which translates to 0.0109%. This is higher than the stated range of 0.0001-0.001%."", ""reference"": ""PMID:25066220"", ""snippet"": ""The total prevalence was 1.09 (95% confidence interval, 1.03-1.15) per 10,000 births."", ""supports"": ""REFUTE""}"
3843	3795	159	Huntington's Disease	Huntingtons_Disease.yaml	prevalence	0	evidence	0	PMID:1535611	PARTIAL		It is concluded that most European populations, both Northern and Southern, show a relatively high prevalence (4-8 per 100,000), and that the disorder may also be frequent in India and parts of central Asia. HD is notably rare in Finland and in Japan, but data for Eastern Asia and Africa are inadequate.	The prevalence of Huntington's Disease varies significantly across different regions, with some populations showing higher prevalence and others showing lower. Therefore, a global percentage of 0.004-0.01 may not accurately reflect the variability seen in different regions.	"{""explanation"": ""The prevalence of Huntington's Disease varies significantly across different regions, with some populations showing higher prevalence and others showing lower. Therefore, a global percentage of 0.004-0.01 may not accurately reflect the variability seen in different regions."", ""reference"": ""PMID:1535611"", ""snippet"": ""It is concluded that most European populations, both Northern and Southern, show a relatively high prevalence (4-8 per 100,000), and that the disorder may also be frequent in India and parts of central Asia. HD is notably rare in Finland and in Japan, but data for Eastern Asia and Africa are inadequate."", ""supports"": ""PARTIAL""}"
3844	3795	159	Huntington's Disease	Huntingtons_Disease.yaml	prevalence	0	evidence	1	PMID:28671137	NO_EVIDENCE		Although the typical age of onset for Huntington's disease (HD) is in the fourth decade, between 4.4-11.5% of individuals with HD have a late onset (over 60 years of age).	This reference discusses the age of onset and not the global prevalence.	"{""explanation"": ""This reference discusses the age of onset and not the global prevalence."", ""reference"": ""PMID:28671137"", ""snippet"": ""Although the typical age of onset for Huntington's disease (HD) is in the fourth decade, between 4.4-11.5% of individuals with HD have a late onset (over 60 years of age)."", ""supports"": ""NO_EVIDENCE""}"
3942	3836	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	prevalence	0	evidence	0	PMID:35372212	REFUTE		From 1990 to 2019, HHD prevalence in China showed decreasing trends in both sexes combined... but significant increases in the age groups of 15-19, 20-24, ..., and 60-64 years.	The study noted significant increasing trends in HHD prevalence in specific age groups, including older adults, but it did not provide specific percentage values within the 10-20 range for adults over 50. Instead, it indicates general trends rather than precise prevalence rates.	"{""explanation"": ""The study noted significant increasing trends in HHD prevalence in specific age groups, including older adults, but it did not provide specific percentage values within the 10-20 range for adults over 50. Instead, it indicates general trends rather than precise prevalence rates."", ""reference"": ""PMID:35372212"", ""snippet"": ""From 1990 to 2019, HHD prevalence in China showed decreasing trends in both sexes combined... but significant increases in the age groups of 15-19, 20-24, ..., and 60-64 years."", ""supports"": ""REFUTE""}"
3943	3836	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	prevalence	0	evidence	1	PMID:9256850	NO_EVIDENCE		CONCLUSIONS: Congestive heart failure is a major public health problem in the United States today as a result of its high and increasing prevalence in the older population...	The reference discusses the prevalence and impact of congestive heart failure in older adults but does not offer specific statistics on the overall prevalence rate of hypertensive heart disease in the 10-20% range for adults over 50.	"{""explanation"": ""The reference discusses the prevalence and impact of congestive heart failure in older adults but does not offer specific statistics on the overall prevalence rate of hypertensive heart disease in the 10-20% range for adults over 50."", ""reference"": ""PMID:9256850"", ""snippet"": ""CONCLUSIONS: Congestive heart failure is a major public health problem in the United States today as a result of its high and increasing prevalence in the older population..."", ""supports"": ""NO_EVIDENCE""}"
4032	3875	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	prevalence	0	evidence	0	PMID:25814232	PARTIAL		For the past 20 years, most data have supported the occurrence of HCM at about 1 in 500.	1 in 500 translates to 0.2%, which supports the statement. However, the statement could be conflicting with the suggestion that HCM might be more common than previously estimated.	"{""explanation"": ""1 in 500 translates to 0.2%, which supports the statement. However, the statement could be conflicting with the suggestion that HCM might be more common than previously estimated."", ""reference"": ""PMID:25814232"", ""snippet"": ""For the past 20 years, most data have supported the occurrence of HCM at about 1 in 500."", ""supports"": ""PARTIAL""}"
4033	3875	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	prevalence	0	evidence	1	PMID:34969871	PARTIAL		Between 2010 and 2018, prevalence increased for ARVC by 180% and HCM by 9%.	While the statement of HCM prevalence being 0.2% is approximately correct, recognition of HCM prevalence seems to have increased, indicating it could be more common now.	"{""explanation"": ""While the statement of HCM prevalence being 0.2% is approximately correct, recognition of HCM prevalence seems to have increased, indicating it could be more common now."", ""reference"": ""PMID:34969871"", ""snippet"": ""Between 2010 and 2018, prevalence increased for ARVC by 180% and HCM by 9%."", ""supports"": ""PARTIAL""}"
4034	3875	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	prevalence	0	evidence	2	PMID:33623987	PARTIAL		Currently, available estimates of prevalence and incidence of CMPs are based on clinical data, collected with a wide variability in population-source, and before the genetic testing evolved as a standard diagnostic tool.	Prevalence estimates for HCM might vary based on the population and advances in diagnostic tools, suggesting that 0.2% could be an estimate but with existing variability.	"{""explanation"": ""Prevalence estimates for HCM might vary based on the population and advances in diagnostic tools, suggesting that 0.2% could be an estimate but with existing variability."", ""reference"": ""PMID:33623987"", ""snippet"": ""Currently, available estimates of prevalence and incidence of CMPs are based on clinical data, collected with a wide variability in population-source, and before the genetic testing evolved as a standard diagnostic tool."", ""supports"": ""PARTIAL""}"
4169	4099	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	prevalence	0	evidence	0	PMID:32554361	REFUTE		It is thought to be underdiagnosed rather than have a rare prevalence.	The literature suggests that Jeavons syndrome is underdiagnosed instead of being extremely rare, indicating a higher prevalence than 0.0001%.	"{""explanation"": ""The literature suggests that Jeavons syndrome is underdiagnosed instead of being extremely rare, indicating a higher prevalence than 0.0001%."", ""reference"": ""PMID:32554361"", ""snippet"": ""It is thought to be underdiagnosed rather than have a rare prevalence."", ""supports"": ""REFUTE""}"
4249	4209	177	Kawasaki Disease	Kawasaki_Disease.yaml	prevalence	0	evidence	0	PMID:10392592	REFUTE		Most children who contract this illness are less than two years old, and 80 percent of affected children are younger than five years of age.	The statement that Kawasaki disease is rare in children under 5 is refuted by the literature, which indicates that 80% of affected children are younger than five years of age.	"{""explanation"": ""The statement that Kawasaki disease is rare in children under 5 is refuted by the literature, which indicates that 80% of affected children are younger than five years of age."", ""reference"": ""PMID:10392592"", ""snippet"": ""Most children who contract this illness are less than two years old, and 80 percent of affected children are younger than five years of age."", ""supports"": ""REFUTE""}"
4250	4209	177	Kawasaki Disease	Kawasaki_Disease.yaml	prevalence	0	evidence	1	PMID:36611091	REFUTE		83% of patients were < 5 years of age and 10% were < 6 months.	The study shows that a significant proportion of Kawasaki disease cases occur in children under 5 years of age, refuting the statement that it is rare in this population.	"{""explanation"": ""The study shows that a significant proportion of Kawasaki disease cases occur in children under 5 years of age, refuting the statement that it is rare in this population."", ""reference"": ""PMID:36611091"", ""snippet"": ""83% of patients were < 5 years of age and 10% were < 6 months."", ""supports"": ""REFUTE""}"
4351	4270	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	prevalence	0	evidence	0	PMID:21449864	REFUTE		The birth prevalence of KS in Victoria is estimated to be 223 per 100,000 males (95% CI, 195-254), with about 50% of cases remaining undiagnosed.	The prevalence of Klinefelter Syndrome (KS) is stated to be 223 per 100,000 males, which translates to 0.223%, refuting the given value of 0.2%.	"{""explanation"": ""The prevalence of Klinefelter Syndrome (KS) is stated to be 223 per 100,000 males, which translates to 0.223%, refuting the given value of 0.2%."", ""reference"": ""PMID:21449864"", ""snippet"": ""The birth prevalence of KS in Victoria is estimated to be 223 per 100,000 males (95% CI, 195-254), with about 50% of cases remaining undiagnosed."", ""supports"": ""REFUTE""}"
4352	4270	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	prevalence	0	evidence	1	PMID:36225116	REFUTE		Klinefelter syndrome (KS) or 47,XXY is the most common sex chromosome aneuploidy (SCA), occurring at a prevalence of 1 in 600 male pregnancies.	The prevalence of KS is described as 1 in 600 male pregnancies, which translates to approximately 0.167%, very close to 0.2% but not precise enough to be considered supportive.	"{""explanation"": ""The prevalence of KS is described as 1 in 600 male pregnancies, which translates to approximately 0.167%, very close to 0.2% but not precise enough to be considered supportive."", ""reference"": ""PMID:36225116"", ""snippet"": ""Klinefelter syndrome (KS) or 47,XXY is the most common sex chromosome aneuploidy (SCA), occurring at a prevalence of 1 in 600 male pregnancies."", ""supports"": ""REFUTE""}"
4451	4355	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	prevalence	0	evidence	0	PMID:35596199	SUPPORT	HUMAN_CLINICAL	This equates to a prevalence of 0.28% in all the children who underwent flexible endoscopy at our institution.	Study reports a 0.28% prevalence among children undergoing flexible endoscopy.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Study reports a 0.28% prevalence among children undergoing flexible endoscopy."", ""reference"": ""PMID:35596199"", ""snippet"": ""This equates to a prevalence of 0.28% in all the children who underwent flexible endoscopy at our institution."", ""supports"": ""SUPPORT""}"
4736	4608	194	Lynch Syndrome	Lynch_Syndrome.yaml	prevalence	0	evidence	0	PMID:33357406	SUPPORT		Due to high prevalence in the general population (1:300),6,7 clear genetic etiology, and potential for prevention through intensified surveillance, pathogenic MMR gene variants are considered clinically actionable.	This directly supports a high general-population carrier prevalence on the order of approximately 0.3%.	"{""explanation"": ""This directly supports a high general-population carrier prevalence on the order of approximately 0.3%."", ""reference"": ""PMID:33357406"", ""snippet"": ""Due to high prevalence in the general population (1:300),6,7 clear genetic etiology, and potential for prevention through intensified surveillance, pathogenic MMR gene variants are considered clinically actionable."", ""supports"": ""SUPPORT""}"
4737	4608	194	Lynch Syndrome	Lynch_Syndrome.yaml	prevalence	0	evidence	1	PMID:34630437	SUPPORT		These Lynch syndrome pathogenic alleles are widely present in humans at a 1:320 population frequency of a single allele	A population frequency of approximately 1:320 corresponds to about 0.3%, consistent with the stated range.	"{""explanation"": ""A population frequency of approximately 1:320 corresponds to about 0.3%, consistent with the stated range."", ""reference"": ""PMID:34630437"", ""snippet"": ""These Lynch syndrome pathogenic alleles are widely present in humans at a 1:320 population frequency of a single allele"", ""supports"": ""SUPPORT""}"
4913	4850	204	Marfan Syndrome	Marfan_Syndrome.yaml	prevalence	0	evidence	0	PMID:21308160	PARTIAL	HUMAN_CLINICAL	Marfan's syndrome is an autosomal dominant condition with an estimated prevalence of one in 10,000 to 20,000 individuals.	The statement is partially supported as the prevalence is given in a range (0.01-0.02) which matches the statement's value range, but it's not explicitly stated as a percentage of the global population.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The statement is partially supported as the prevalence is given in a range (0.01-0.02) which matches the statement's value range, but it's not explicitly stated as a percentage of the global population."", ""reference"": ""PMID:21308160"", ""snippet"": ""Marfan's syndrome is an autosomal dominant condition with an estimated prevalence of one in 10,000 to 20,000 individuals."", ""supports"": ""PARTIAL""}"
4914	4850	204	Marfan Syndrome	Marfan_Syndrome.yaml	prevalence	0	evidence	1	PMID:26631233	REFUTE	HUMAN_CLINICAL	We identified a total of 1628 persons with possible Marfan syndrome. We confirmed the diagnosis in 412, whereof 46 were deceased, yielding a maximum prevalence of 6.5/100,000 at the end of 2014.	This study reports a maximum prevalence of 6.5/100,000, which is lower than the 0.01-0.02 percentage range stated in the question.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study reports a maximum prevalence of 6.5/100,000, which is lower than the 0.01-0.02 percentage range stated in the question."", ""reference"": ""PMID:26631233"", ""snippet"": ""We identified a total of 1628 persons with possible Marfan syndrome. We confirmed the diagnosis in 412, whereof 46 were deceased, yielding a maximum prevalence of 6.5/100,000 at the end of 2014."", ""supports"": ""REFUTE""}"
4953	4864	205	Meckel Diverticulum	Meckel_Diverticulum.yaml	prevalence	0	evidence	0	PMID:27492813	SUPPORT		Meckel's diverticulum is the most frequent congenital malformation of the gastrointestinal tract, occurring in 2% of the general population.	This confirms the 2% prevalence rate in the general population.	"{""explanation"": ""This confirms the 2% prevalence rate in the general population."", ""reference"": ""PMID:27492813"", ""snippet"": ""Meckel's diverticulum is the most frequent congenital malformation of the gastrointestinal tract, occurring in 2% of the general population."", ""supports"": ""SUPPORT""}"
4954	4864	205	Meckel Diverticulum	Meckel_Diverticulum.yaml	prevalence	0	evidence	1	PMID:15026601	SUPPORT		Meckel diverticulum is the most common congenital anomaly of the gastrointestinal tract, occurring in 2%-3% of the population.	This confirms the 2-3% prevalence range.	"{""explanation"": ""This confirms the 2-3% prevalence range."", ""reference"": ""PMID:15026601"", ""snippet"": ""Meckel diverticulum is the most common congenital anomaly of the gastrointestinal tract, occurring in 2%-3% of the population."", ""supports"": ""SUPPORT""}"
4955	4864	205	Meckel Diverticulum	Meckel_Diverticulum.yaml	prevalence	0	evidence	2	PMID:15026601	SUPPORT		The formation of Meckel diverticulum occurs with equal frequency in both sexes, but symptoms from complications are more common in male patients.	This documents the sex-specific differences in complication rates despite equal occurrence.	"{""explanation"": ""This documents the sex-specific differences in complication rates despite equal occurrence."", ""reference"": ""PMID:15026601"", ""snippet"": ""The formation of Meckel diverticulum occurs with equal frequency in both sexes, but symptoms from complications are more common in male patients."", ""supports"": ""SUPPORT""}"
5029	4919	206	Meckel Syndrome	Meckel_Syndrome.yaml	prevalence	0	evidence	0	PMID:25182137	SUPPORT	HUMAN_CLINICAL	The mean prevalence was 2.6 per 100,000 births in a subset of registries with good ascertainment.	This population-based study provides a prevalence estimate for MKS.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This population-based study provides a prevalence estimate for MKS."", ""reference"": ""PMID:25182137"", ""snippet"": ""The mean prevalence was 2.6 per 100,000 births in a subset of registries with good ascertainment."", ""supports"": ""SUPPORT""}"
5088	5008	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	prevalence	0	evidence	0	PMID:26618123	PARTIAL		Acral lentiginous melanoma occurred most frequently ... Corresponding to previous findings, nodular melanoma tended to occur at a higher stage than other types.	This study discusses the epidemiology of cutaneous melanoma in Korea, showing the clinical and histopathological patterns of primary cutaneous melanoma.	"{""explanation"": ""This study discusses the epidemiology of cutaneous melanoma in Korea, showing the clinical and histopathological patterns of primary cutaneous melanoma."", ""reference"": ""PMID:26618123"", ""snippet"": ""Acral lentiginous melanoma occurred most frequently ... Corresponding to previous findings, nodular melanoma tended to occur at a higher stage than other types."", ""supports"": ""PARTIAL""}"
5089	5008	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	prevalence	0	evidence	1	PMID:17377384	PARTIAL		The observations of this study also suggest that the risk of appearance of MM, at least in childhood and adolescence, is limited for medium-sized CMN.	This reference suggests that the risk of melanoma (MM) from medium-sized congenital melanocytic nevi (CMN) is limited in childhood and adolescence, but does not provide a specific prevalence percentage.	"{""explanation"": ""This reference suggests that the risk of melanoma (MM) from medium-sized congenital melanocytic nevi (CMN) is limited in childhood and adolescence, but does not provide a specific prevalence percentage."", ""reference"": ""PMID:17377384"", ""snippet"": ""The observations of this study also suggest that the risk of appearance of MM, at least in childhood and adolescence, is limited for medium-sized CMN."", ""supports"": ""PARTIAL""}"
5090	5008	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	prevalence	0	evidence	2	PMID:19880040	PARTIAL		Some risk factors for melanoma include xeroderma pigmentosum, giant congenital melanocytic nevi, dysplastic nevus syndrome, atypical nevi, many acquired melanocytic nevi, family history of melanoma, and immunosuppression.	While this source lists giant congenital melanocytic nevi as a risk factor, it does not directly address the prevalence of melanoma in these nevi.	"{""explanation"": ""While this source lists giant congenital melanocytic nevi as a risk factor, it does not directly address the prevalence of melanoma in these nevi."", ""reference"": ""PMID:19880040"", ""snippet"": ""Some risk factors for melanoma include xeroderma pigmentosum, giant congenital melanocytic nevi, dysplastic nevus syndrome, atypical nevi, many acquired melanocytic nevi, family history of melanoma, and immunosuppression."", ""supports"": ""PARTIAL""}"
5091	5008	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	prevalence	0	evidence	3	PMID:35561684	PARTIAL		Their most dangerous consequence is progression to melanoma. This risk often triggers preemptive extensive surgical excisions in childhood, producing severe lifelong challenges.	The reference acknowledges the high risk of melanoma progression in giant congenital melanocytic nevi but does not quantify the prevalence in the general population.	"{""explanation"": ""The reference acknowledges the high risk of melanoma progression in giant congenital melanocytic nevi but does not quantify the prevalence in the general population."", ""reference"": ""PMID:35561684"", ""snippet"": ""Their most dangerous consequence is progression to melanoma. This risk often triggers preemptive extensive surgical excisions in childhood, producing severe lifelong challenges."", ""supports"": ""PARTIAL""}"
5092	5008	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	prevalence	0	evidence	4	PMID:36303818	PARTIAL		The congenital melanocytic nevus: a rare clinical image.	This case report emphasizes the rarity of congenital melanocytic nevi progressing to melanoma, but no specific prevalence data is provided for the general population.	"{""explanation"": ""This case report emphasizes the rarity of congenital melanocytic nevi progressing to melanoma, but no specific prevalence data is provided for the general population."", ""reference"": ""PMID:36303818"", ""snippet"": ""The congenital melanocytic nevus: a rare clinical image."", ""supports"": ""PARTIAL""}"
5280	5169	216	Monkeypox	Monkeypox.yaml	prevalence	0	evidence	0	PMID:36007687	SUPPORT		MPX is endemic in central and western Africa.	The abstract directly states that monkeypox (MPX) is endemic in Central and West Africa.	"{""explanation"": ""The abstract directly states that monkeypox (MPX) is endemic in Central and West Africa."", ""reference"": ""PMID:36007687"", ""snippet"": ""MPX is endemic in central and western Africa."", ""supports"": ""SUPPORT""}"
5281	5169	216	Monkeypox	Monkeypox.yaml	prevalence	0	evidence	1	PMID:35762024	SUPPORT		The disease is known to cause severe outcome in children, pregnant women, and immunocompromised hosts and this group need to be given special attention. The monkeypox disease outbreak (2022) in non-endemic countries should be used as an opportunity by India and other low and middle income countries to strengthen public health surveillance and health system capacity for outbreak and epidemic preparedness and response.	The reference suggests that while the 2022 outbreak occurred in non-endemic countries, monkeypox remains endemic in Central and West Africa, supporting the statement about varying prevalence by outbreak and its endemic status in these regions.	"{""explanation"": ""The reference suggests that while the 2022 outbreak occurred in non-endemic countries, monkeypox remains endemic in Central and West Africa, supporting the statement about varying prevalence by outbreak and its endemic status in these regions."", ""reference"": ""PMID:35762024"", ""snippet"": ""The disease is known to cause severe outcome in children, pregnant women, and immunocompromised hosts and this group need to be given special attention. The monkeypox disease outbreak (2022) in non-endemic countries should be used as an opportunity by India and other low and middle income countries to strengthen public health surveillance and health system capacity for outbreak and epidemic preparedness and response."", ""supports"": ""SUPPORT""}"
5410	5239	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	prevalence	0	evidence	0	PMID:30679040	WRONG_STATEMENT		In 2016, there were 2 221 188 prevalent cases of multiple sclerosis ... globally, which corresponded to a 104% ... increase in the age-standardised prevalence since 1990	The statement claims that the global prevalence of multiple sclerosis is 0.1%, but the literature indicates that the prevalence is much higher.	"{""explanation"": ""The statement claims that the global prevalence of multiple sclerosis is 0.1%, but the literature indicates that the prevalence is much higher."", ""reference"": ""PMID:30679040"", ""snippet"": ""In 2016, there were 2 221 188 prevalent cases of multiple sclerosis ... globally, which corresponded to a 104% ... increase in the age-standardised prevalence since 1990"", ""supports"": ""WRONG_STATEMENT""}"
5411	5239	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	prevalence	0	evidence	1	PMID:37059571	WRONG_STATEMENT		Prevalence rates in countries with predominantly white populations are considerably higher and have increased over time, reaching 115 cases/100,000 population in 2015.	The statement's percentage is incorrect as prevalence rates in various populations are much higher than 0.1%.	"{""explanation"": ""The statement's percentage is incorrect as prevalence rates in various populations are much higher than 0.1%."", ""reference"": ""PMID:37059571"", ""snippet"": ""Prevalence rates in countries with predominantly white populations are considerably higher and have increased over time, reaching 115 cases/100,000 population in 2015."", ""supports"": ""WRONG_STATEMENT""}"
5506	5289	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	prevalence	0	evidence	0	PMID:37651206	SUPPORT		Multisystem inflammatory syndrome in children (MIS-C) is a rare but life-threatening hyperinflammatory condition induced by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes pediatric COVID-19 (pCOVID-19).	The literature explicitly describes MIS-C as a rare condition in children.	"{""explanation"": ""The literature explicitly describes MIS-C as a rare condition in children."", ""reference"": ""PMID:37651206"", ""snippet"": ""Multisystem inflammatory syndrome in children (MIS-C) is a rare but life-threatening hyperinflammatory condition induced by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes pediatric COVID-19 (pCOVID-19)."", ""supports"": ""SUPPORT""}"
5507	5289	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	prevalence	0	evidence	1	PMID:37054392	SUPPORT		MIS-C incidence was 1.03 of 100,000 age-specific population and 0.04 of 1000 recorded SARS-CoV-2 infections.	The incidence rates provided in the study indicate that MIS-C is a rare condition among children.	"{""explanation"": ""The incidence rates provided in the study indicate that MIS-C is a rare condition among children."", ""reference"": ""PMID:37054392"", ""snippet"": ""MIS-C incidence was 1.03 of 100,000 age-specific population and 0.04 of 1000 recorded SARS-CoV-2 infections."", ""supports"": ""SUPPORT""}"
5683	5487	229	Nephronophthisis	Nephronophthisis.yaml	prevalence	0	evidence	0	PMID:29717526	NO_EVIDENCE		Nephronophthisis is an autosomal recessive cystic kidney disease and one of the most common genetic disorders causing end-stage renal disease in children. Nephronophthisis is a genetically heterogenous disorder with more than 25 identified genes. In 10%-20% of cases, there are additional features of a ciliopathy syndrome, such as retinal defects, liver fibrosis, skeletal abnormalities, and brain developmental disorders.	The provided literature discusses the genetic heterogeneity and associated features of nephronophthisis but does not provide information about its global prevalence.	"{""explanation"": ""The provided literature discusses the genetic heterogeneity and associated features of nephronophthisis but does not provide information about its global prevalence."", ""reference"": ""PMID:29717526"", ""snippet"": ""Nephronophthisis is an autosomal recessive cystic kidney disease and one of the most common genetic disorders causing end-stage renal disease in children. Nephronophthisis is a genetically heterogenous disorder with more than 25 identified genes. In 10%-20% of cases, there are additional features of a ciliopathy syndrome, such as retinal defects, liver fibrosis, skeletal abnormalities, and brain developmental disorders."", ""supports"": ""NO_EVIDENCE""}"
5684	5487	229	Nephronophthisis	Nephronophthisis.yaml	prevalence	0	evidence	1	PMID:25514144	NO_EVIDENCE		According to the official health statistics, Taiwan has the highest prevalence of end stage renal disease (ESRD) in the world. Each year, around 60,000 ESRD patients in Taiwan consume 6% of the national insurance budget for dialysis treatment. The prevalence of chronic kidney disease (CKD) has been climbing during 2008-2012.	The article discusses the prevalence of end-stage renal disease in Taiwan but does not provide specific prevalence rates for nephronophthisis.	"{""explanation"": ""The article discusses the prevalence of end-stage renal disease in Taiwan but does not provide specific prevalence rates for nephronophthisis."", ""reference"": ""PMID:25514144"", ""snippet"": ""According to the official health statistics, Taiwan has the highest prevalence of end stage renal disease (ESRD) in the world. Each year, around 60,000 ESRD patients in Taiwan consume 6% of the national insurance budget for dialysis treatment. The prevalence of chronic kidney disease (CKD) has been climbing during 2008-2012."", ""supports"": ""NO_EVIDENCE""}"
6115	5961	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	prevalence	0	evidence	0	PMID:25990962	PARTIAL		The overall IgG prevalence in the 1008 representative sera samples was 61.4% and the age-adjusted prevalence rate was 58.2%.	The study provides data on the prevalence of Parvovirus B19 infection in the Israeli population, indicating that a significant portion of the population has been exposed to the virus. However, this is specific to Israel and may not represent the global population.	"{""explanation"": ""The study provides data on the prevalence of Parvovirus B19 infection in the Israeli population, indicating that a significant portion of the population has been exposed to the virus. However, this is specific to Israel and may not represent the global population."", ""reference"": ""PMID:25990962"", ""snippet"": ""The overall IgG prevalence in the 1008 representative sera samples was 61.4% and the age-adjusted prevalence rate was 58.2%."", ""supports"": ""PARTIAL""}"
6116	5961	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	prevalence	0	evidence	1	PMID:27806994	PARTIAL		These viruses are prevalent worldwide and are culturable in vitro, and serological and molecular assays are available but require careful interpretation of results.	The article mentions that Parvovirus B19 is prevalent worldwide, supporting the statement to some extent. However, it does not provide specific global prevalence percentages.	"{""explanation"": ""The article mentions that Parvovirus B19 is prevalent worldwide, supporting the statement to some extent. However, it does not provide specific global prevalence percentages."", ""reference"": ""PMID:27806994"", ""snippet"": ""These viruses are prevalent worldwide and are culturable in vitro, and serological and molecular assays are available but require careful interpretation of results."", ""supports"": ""PARTIAL""}"
6117	5961	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	prevalence	0	evidence	2	PMID:21040396	PARTIAL		Human parvovirus B19 infection is widespread. Approximately 30-50% of pregnant women are nonimmune, and vertical transmission is common following maternal infection in pregnancy.	The article indicates that Parvovirus B19 infection is widespread and provides specific data on nonimmune pregnant women, suggesting significant exposure rates. However, it does not provide a comprehensive global percentage.	"{""explanation"": ""The article indicates that Parvovirus B19 infection is widespread and provides specific data on nonimmune pregnant women, suggesting significant exposure rates. However, it does not provide a comprehensive global percentage."", ""reference"": ""PMID:21040396"", ""snippet"": ""Human parvovirus B19 infection is widespread. Approximately 30-50% of pregnant women are nonimmune, and vertical transmission is common following maternal infection in pregnancy."", ""supports"": ""PARTIAL""}"
6118	5961	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	prevalence	0	evidence	3	PMID:31266615	NO_EVIDENCE		Hepatitis B virus (HBV) infection is a global health burden.	This article focuses on Hepatitis B virus infection and does not provide information relevant to Parvovirus B19 infection.	"{""explanation"": ""This article focuses on Hepatitis B virus infection and does not provide information relevant to Parvovirus B19 infection."", ""reference"": ""PMID:31266615"", ""snippet"": ""Hepatitis B virus (HBV) infection is a global health burden."", ""supports"": ""NO_EVIDENCE""}"
6119	5961	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	prevalence	0	evidence	4	PMID:36619750	PARTIAL		The HPV B19 infection rate in hospitalized patients suspected of microbial infection was 2.22%.	The study provides specific data on the infection rate among hospitalized patients, which suggests that Parvovirus B19 can be present in specific populations. However, it does not provide global prevalence data.	"{""explanation"": ""The study provides specific data on the infection rate among hospitalized patients, which suggests that Parvovirus B19 can be present in specific populations. However, it does not provide global prevalence data."", ""reference"": ""PMID:36619750"", ""snippet"": ""The HPV B19 infection rate in hospitalized patients suspected of microbial infection was 2.22%."", ""supports"": ""PARTIAL""}"
6120	5961	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	prevalence	0	evidence	5	PMID:30843782	PARTIAL		Parvovirus B19 (B19V) transmission may occur through blood transfusion as a result of asymptomatic viral persistence in blood donors.	The study indicates that Parvovirus B19 can persist in blood donors, suggesting potential widespread exposure. However, it does not provide specific global prevalence percentages.	"{""explanation"": ""The study indicates that Parvovirus B19 can persist in blood donors, suggesting potential widespread exposure. However, it does not provide specific global prevalence percentages."", ""reference"": ""PMID:30843782"", ""snippet"": ""Parvovirus B19 (B19V) transmission may occur through blood transfusion as a result of asymptomatic viral persistence in blood donors."", ""supports"": ""PARTIAL""}"
6249	6051	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	prevalence	0	evidence	0	PMID:8914632	SUPPORT		The incidence of peroxisome-deficient disorders was estimated to be approximately 1 in 800,000 births which is far less than that in the USA.	The literature quantifies peroxisome-deficient disorders as occurring approximately 1 in 800,000 births globally, supporting the claim that the prevalence is very rare.	"{""explanation"": ""The literature quantifies peroxisome-deficient disorders as occurring approximately 1 in 800,000 births globally, supporting the claim that the prevalence is very rare."", ""reference"": ""PMID:8914632"", ""snippet"": ""The incidence of peroxisome-deficient disorders was estimated to be approximately 1 in 800,000 births which is far less than that in the USA."", ""supports"": ""SUPPORT""}"
6250	6051	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	prevalence	0	evidence	1	PMID:34628380	SUPPORT		The incidence of rare diseases is approximately two cases per 10,000 people.	The literature states that the incidence of rare diseases is approximately two cases per 10,000 people, which aligns with the statement that Peroxisome Biogenesis Disorders are very rare globally.	"{""explanation"": ""The literature states that the incidence of rare diseases is approximately two cases per 10,000 people, which aligns with the statement that Peroxisome Biogenesis Disorders are very rare globally."", ""reference"": ""PMID:34628380"", ""snippet"": ""The incidence of rare diseases is approximately two cases per 10,000 people."", ""supports"": ""SUPPORT""}"
6354	6184	261	Pick Disease	Pick_Disease.yaml	prevalence	0	evidence	0	PMID:17076146	NO_EVIDENCE			The provided literature focused on Pick's disease, but no specific prevalence data is given.	"{""explanation"": ""The provided literature focused on Pick's disease, but no specific prevalence data is given."", ""reference"": ""PMID:17076146"", ""supports"": ""NO_EVIDENCE""}"
6355	6184	261	Pick Disease	Pick_Disease.yaml	prevalence	0	evidence	1	PMID:18090424	NO_EVIDENCE			This historical summary of Pick complex does not provide relevant prevalence figures necessary to support or refute the given statement.	"{""explanation"": ""This historical summary of Pick complex does not provide relevant prevalence figures necessary to support or refute the given statement."", ""reference"": ""PMID:18090424"", ""supports"": ""NO_EVIDENCE""}"
6378	6206	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	prevalence	0	evidence	0	PMID:37549288	SUPPORT		We compiled a unique dataset of host occurrences (~86000 records) and disease infections (~400 cases) covering the entire Pan-Amazonia and employed different modeling and statistical tools to unveil the spatial distribution of PE's key animal hosts.	The modeling study documents hundreds of human infections across Pan-Amazonia, indicating focal endemicity.	"{""explanation"": ""The modeling study documents hundreds of human infections across Pan-Amazonia, indicating focal endemicity."", ""reference"": ""PMID:37549288"", ""snippet"": ""We compiled a unique dataset of host occurrences (~86000 records) and disease infections (~400 cases) covering the entire Pan-Amazonia and employed different modeling and statistical tools to unveil the spatial distribution of PE's key animal hosts."", ""supports"": ""SUPPORT""}"
6525	6372	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	prevalence	0	evidence	0	PMID:34454779	PARTIAL		Primary ciliary dyskinesia (PCD) is a rare hereditary disease.	The study mentions that PCD is a rare disease but does not provide specific global prevalence rates.	"{""explanation"": ""The study mentions that PCD is a rare disease but does not provide specific global prevalence rates."", ""reference"": ""PMID:34454779"", ""snippet"": ""Primary ciliary dyskinesia (PCD) is a rare hereditary disease."", ""supports"": ""PARTIAL""}"
6526	6372	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	prevalence	0	evidence	1	PMID:31971980	PARTIAL		Primary ciliary dyskinesia (PCD) is a rare autosomal recessive disease with low prevalence in pediatrics.	The study confirms that PCD is rare but does not provide exact global prevalence figures.	"{""explanation"": ""The study confirms that PCD is rare but does not provide exact global prevalence figures."", ""reference"": ""PMID:31971980"", ""snippet"": ""Primary ciliary dyskinesia (PCD) is a rare autosomal recessive disease with low prevalence in pediatrics."", ""supports"": ""PARTIAL""}"
6527	6372	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	prevalence	0	evidence	2	PMID:32662935	PARTIAL		Cilia are cell membrane-bound organelles responsible for airway mucus clearance, establishment of left-right organ asymmetry, cardiogenesis, and many other functions in utero.	The study discusses the functions of cilia and mentions ciliary dyskinesia but does not provide prevalence data.	"{""explanation"": ""The study discusses the functions of cilia and mentions ciliary dyskinesia but does not provide prevalence data."", ""reference"": ""PMID:32662935"", ""snippet"": ""Cilia are cell membrane-bound organelles responsible for airway mucus clearance, establishment of left-right organ asymmetry, cardiogenesis, and many other functions in utero."", ""supports"": ""PARTIAL""}"
6528	6372	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	prevalence	0	evidence	3	PMID:30792130	PARTIAL		Primary ciliary dyskinesia (PCD), also known as immotile-cilia syndrome, is a rare genetic disease.	The study acknowledges that PCD is a rare genetic disease but does not specify the global prevalence.	"{""explanation"": ""The study acknowledges that PCD is a rare genetic disease but does not specify the global prevalence."", ""reference"": ""PMID:30792130"", ""snippet"": ""Primary ciliary dyskinesia (PCD), also known as immotile-cilia syndrome, is a rare genetic disease."", ""supports"": ""PARTIAL""}"
6529	6372	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	prevalence	0	evidence	4	PMID:26826908	NO_EVIDENCE		Primary Ciliary Dyskinesia.	This reference does not provide information on the global prevalence of PCD.	"{""explanation"": ""This reference does not provide information on the global prevalence of PCD."", ""reference"": ""PMID:26826908"", ""snippet"": ""Primary Ciliary Dyskinesia."", ""supports"": ""NO_EVIDENCE""}"
6530	6372	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	prevalence	0	evidence	5	PMID:15917207	NO_EVIDENCE		Cilia are classified according to their microtubule components as 9+2 (motile) and 9+0 (primary) cilia.	This reference discusses cilia and their functions but does not provide prevalence data for PCD.	"{""explanation"": ""This reference discusses cilia and their functions but does not provide prevalence data for PCD."", ""reference"": ""PMID:15917207"", ""snippet"": ""Cilia are classified according to their microtubule components as 9+2 (motile) and 9+0 (primary) cilia."", ""supports"": ""NO_EVIDENCE""}"
6531	6372	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	prevalence	0	evidence	6	PMID:29905515	NO_EVIDENCE		This document presents the American Thoracic Society clinical practice guidelines for the diagnosis of primary ciliary dyskinesia (PCD).	This reference focuses on diagnostic guidelines and does not provide prevalence data.	"{""explanation"": ""This reference focuses on diagnostic guidelines and does not provide prevalence data."", ""reference"": ""PMID:29905515"", ""snippet"": ""This document presents the American Thoracic Society clinical practice guidelines for the diagnosis of primary ciliary dyskinesia (PCD)."", ""supports"": ""NO_EVIDENCE""}"
6532	6372	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	prevalence	0	evidence	7	PMID:31430425	NO_EVIDENCE		The objective of this study was to evaluate the prevalence of chronic rhinosinusitis (CRS) and its characteristics in bronchiectasis patients suspected of harboring ciliary dyskinesia.	This study evaluates CRS in patients suspected of having ciliary dyskinesia but does not provide global prevalence data for PCD.	"{""explanation"": ""This study evaluates CRS in patients suspected of having ciliary dyskinesia but does not provide global prevalence data for PCD."", ""reference"": ""PMID:31430425"", ""snippet"": ""The objective of this study was to evaluate the prevalence of chronic rhinosinusitis (CRS) and its characteristics in bronchiectasis patients suspected of harboring ciliary dyskinesia."", ""supports"": ""NO_EVIDENCE""}"
6533	6372	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	prevalence	0	evidence	8	PMID:36588099	NO_EVIDENCE		There are no recent data on primary ciliary dyskinesia (PCD) distribution, diagnosis and treatment in Italy.	This reference discusses PCD in Italy but does not provide global prevalence data.	"{""explanation"": ""This reference discusses PCD in Italy but does not provide global prevalence data."", ""reference"": ""PMID:36588099"", ""snippet"": ""There are no recent data on primary ciliary dyskinesia (PCD) distribution, diagnosis and treatment in Italy."", ""supports"": ""NO_EVIDENCE""}"
6617	6453	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	prevalence	0	evidence	0	PMID:11338097	SUPPORT		Non-Hodgkin's lymphoma (NHL) arising primarily in the palatine tonsil is uncommon.	The literature explicitly states that primary non-Hodgkin's lymphoma of the palatine tonsil is uncommon, which supports the statement that primary tonsillar lymphoma is rare in the general population.	"{""explanation"": ""The literature explicitly states that primary non-Hodgkin's lymphoma of the palatine tonsil is uncommon, which supports the statement that primary tonsillar lymphoma is rare in the general population."", ""reference"": ""PMID:11338097"", ""snippet"": ""Non-Hodgkin's lymphoma (NHL) arising primarily in the palatine tonsil is uncommon."", ""supports"": ""SUPPORT""}"
6618	6453	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	prevalence	0	evidence	1	PMID:30639969	SUPPORT		One hundred forty-one cases of tonsil cancer were identified... Lymphoma remains the predominant histological type of cancer.	Although this reference discusses pediatric tonsillar cancers, it mentions that lymphoma is a predominant type. However, the overall context supports the rarity of primary tonsillar lymphoma, as it is a specific and less common type of cancer within a rare subset.	"{""explanation"": ""Although this reference discusses pediatric tonsillar cancers, it mentions that lymphoma is a predominant type. However, the overall context supports the rarity of primary tonsillar lymphoma, as it is a specific and less common type of cancer within a rare subset."", ""reference"": ""PMID:30639969"", ""snippet"": ""One hundred forty-one cases of tonsil cancer were identified... Lymphoma remains the predominant histological type of cancer."", ""supports"": ""SUPPORT""}"
6707	6510	276	Proteus syndrome	Proteus_syndrome.yaml	prevalence	0	evidence	0	DOI:10.1186/s13023-023-03013-9	SUPPORT		Proteus syndrome is an ultra-rare mosaic overgrowth disorder.	This statement characterizes Proteus syndrome as ultra-rare.	"{""explanation"": ""This statement characterizes Proteus syndrome as ultra-rare."", ""reference"": ""DOI:10.1186/s13023-023-03013-9"", ""snippet"": ""Proteus syndrome is an ultra-rare mosaic overgrowth disorder."", ""supports"": ""SUPPORT""}"
6708	6510	276	Proteus syndrome	Proteus_syndrome.yaml	prevalence	0	evidence	1	DOI:10.1055/a-2300-7002	SUPPORT		Proteus syndrome (PS) is an exceptionally uncommon genetic disorder that has been documented in only approximately 250 cases in the literature spanning the past four decades.	This provides a literature-based estimate of reported case counts.	"{""explanation"": ""This provides a literature-based estimate of reported case counts."", ""reference"": ""DOI:10.1055/a-2300-7002"", ""snippet"": ""Proteus syndrome (PS) is an exceptionally uncommon genetic disorder that has been documented in only approximately 250 cases in the literature spanning the past four decades."", ""supports"": ""SUPPORT""}"
6709	6511	276	Proteus syndrome	Proteus_syndrome.yaml	prevalence	1	evidence	0	PMID:33987133	SUPPORT		It has an estimated prevalence of less than 1/1,000,000 live births.	This case report provides a population prevalence estimate for Proteus syndrome.	"{""explanation"": ""This case report provides a population prevalence estimate for Proteus syndrome."", ""reference"": ""PMID:33987133"", ""snippet"": ""It has an estimated prevalence of less than 1/1,000,000 live births."", ""supports"": ""SUPPORT""}"
6788	6695	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	prevalence	0	evidence	0	PMID:29448987	SUPPORT	HUMAN_CLINICAL	The incidence of RS is unknown as no universally accepted definition exists, but it is frequently underdiagnosed.	This review states that the incidence is unknown and underdiagnosed.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This review states that the incidence is unknown and underdiagnosed."", ""reference"": ""PMID:29448987"", ""snippet"": ""The incidence of RS is unknown as no universally accepted definition exists, but it is frequently underdiagnosed."", ""supports"": ""SUPPORT""}"
6789	6696	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	prevalence	1	evidence	0	PMID:40738722	SUPPORT	HUMAN_CLINICAL	Among 90 patients included, 30 (33.3%) developed RS.	This provides an observed occurrence rate in a defined PN cohort.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This provides an observed occurrence rate in a defined PN cohort."", ""reference"": ""PMID:40738722"", ""snippet"": ""Among 90 patients included, 30 (33.3%) developed RS."", ""supports"": ""SUPPORT""}"
6790	6697	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	prevalence	2	evidence	0	PMID:41007088	SUPPORT	HUMAN_CLINICAL	prevalence rates ranging from 8.7% to 34.8%.	This meta-analysis reports the prevalence range of refeeding syndrome in inpatient SAM children.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This meta-analysis reports the prevalence range of refeeding syndrome in inpatient SAM children."", ""reference"": ""PMID:41007088"", ""snippet"": ""prevalence rates ranging from 8.7% to 34.8%."", ""supports"": ""SUPPORT""}"
6791	6698	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	prevalence	3	evidence	0	PMID:41173142	SUPPORT	HUMAN_CLINICAL	A total of 121 patients were evaluated, of whom 38.8% presented with RS	This study reports the proportion of hospitalized adult and elderly patients with refeeding syndrome.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study reports the proportion of hospitalized adult and elderly patients with refeeding syndrome."", ""reference"": ""PMID:41173142"", ""snippet"": ""A total of 121 patients were evaluated, of whom 38.8% presented with RS"", ""supports"": ""SUPPORT""}"
6956	6799	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	prevalence	0	evidence	0	PMID:24217093	PARTIAL		A study in the UK found the population minimum prevalence of RA is 1.16% in women and 0.44% in men. In Australia, the estimated prevalence is 0.6%.	While the prevalence of RA in the UK and Australia provides values that fall both below and slightly within the stated range (0.5-1.0%), it does not consistently support the global prevalence within that range.	"{""explanation"": ""While the prevalence of RA in the UK and Australia provides values that fall both below and slightly within the stated range (0.5-1.0%), it does not consistently support the global prevalence within that range."", ""reference"": ""PMID:24217093"", ""snippet"": ""A study in the UK found the population minimum prevalence of RA is 1.16% in women and 0.44% in men. In Australia, the estimated prevalence is 0.6%."", ""supports"": ""PARTIAL""}"
6957	6799	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	prevalence	0	evidence	1	PMID:32712723	REFUTE		According to the most recently published systematic reviews, pooled prevalence estimates for RA are 0.38% in North America, and 0.21 to 0.25% in European subregions.	The prevalence estimates for North America and European subregions are significantly below the stated range (0.5-1.0%), thus not supporting the statement.	"{""explanation"": ""The prevalence estimates for North America and European subregions are significantly below the stated range (0.5-1.0%), thus not supporting the statement."", ""reference"": ""PMID:32712723"", ""snippet"": ""According to the most recently published systematic reviews, pooled prevalence estimates for RA are 0.38% in North America, and 0.21 to 0.25% in European subregions."", ""supports"": ""REFUTE""}"
7005	6820	291	Roifman-syndrome	Roifman-syndrome.yaml	prevalence	0	evidence	0	PMID:35450878	SUPPORT		Roifman syndrome is a rare autosomal recessive inherited syndromic immunodeficiency.	The literature directly states that Roifman syndrome is rare.	"{""explanation"": ""The literature directly states that Roifman syndrome is rare."", ""reference"": ""PMID:35450878"", ""snippet"": ""Roifman syndrome is a rare autosomal recessive inherited syndromic immunodeficiency."", ""supports"": ""SUPPORT""}"
7006	6820	291	Roifman-syndrome	Roifman-syndrome.yaml	prevalence	0	evidence	1	PMID:31527858	SUPPORT		Rare diseases, an emerging global public health priority, require an evidence-based estimate of the global point prevalence to inform public policy.	This reference discusses the prevalence of rare diseases globally, which supports the statement that Roifman syndrome, being a rare disease, affects a small percentage of the global population.	"{""explanation"": ""This reference discusses the prevalence of rare diseases globally, which supports the statement that Roifman syndrome, being a rare disease, affects a small percentage of the global population."", ""reference"": ""PMID:31527858"", ""snippet"": ""Rare diseases, an emerging global public health priority, require an evidence-based estimate of the global point prevalence to inform public policy."", ""supports"": ""SUPPORT""}"
7065	6870	293	Salla Disease	Salla_Disease.yaml	prevalence	0	evidence	0	PMID:33862140	SUPPORT	HUMAN_CLINICAL	Around 200 FSASD cases are reported worldwide, with the clinical spectrum ranging from a severe infantile onset form, often lethal in early childhood, to a mild, less severe form with subjects living into adulthood, also called Salla disease.	Comprehensive NIH-led consortium review of FSASD epidemiology documents global case numbers and the clinical spectrum with Salla disease as the milder end of the spectrum.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Comprehensive NIH-led consortium review of FSASD epidemiology documents global case numbers and the clinical spectrum with Salla disease as the milder end of the spectrum."", ""reference"": ""PMID:33862140"", ""snippet"": ""Around 200 FSASD cases are reported worldwide, with the clinical spectrum ranging from a severe infantile onset form, often lethal in early childhood, to a mild, less severe form with subjects living into adulthood, also called Salla disease."", ""supports"": ""SUPPORT""}"
7066	6870	293	Salla Disease	Salla_Disease.yaml	prevalence	0	evidence	1	PMID:29875421	SUPPORT	HUMAN_CLINICAL	Median age at disease onset was 0.17 years. Median age at diagnosis was 3 years with a median diagnostic delay of 2.5 years. Median survival was 11 years.	Large cross-sectional quantitative analysis of 116 published FSASD cases documents the natural history including significant diagnostic delay from infancy to early childhood, and median survival of 11 years across the clinical spectrum.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Large cross-sectional quantitative analysis of 116 published FSASD cases documents the natural history including significant diagnostic delay from infancy to early childhood, and median survival of 11 years across the clinical spectrum."", ""reference"": ""PMID:29875421"", ""snippet"": ""Median age at disease onset was 0.17 years. Median age at diagnosis was 3 years with a median diagnostic delay of 2.5 years. Median survival was 11 years."", ""supports"": ""SUPPORT""}"
7067	6871	293	Salla Disease	Salla_Disease.yaml	prevalence	1	evidence	0	PMID:33862140	SUPPORT	HUMAN_CLINICAL	Around 200 FSASD cases are reported worldwide, with the clinical spectrum ranging from a severe infantile onset form, often lethal in early childhood, to a mild, less severe form with subjects living into adulthood, also called Salla disease. The pathobiology of FSASD remains poorly understood and FSASD is likely underdiagnosed.	Comprehensive FSASD epidemiology review showing that the majority of reported cases are of Finnish or Swedish ancestry, demonstrating the founder effect and geographic clustering of Salla disease in Scandinavian populations.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Comprehensive FSASD epidemiology review showing that the majority of reported cases are of Finnish or Swedish ancestry, demonstrating the founder effect and geographic clustering of Salla disease in Scandinavian populations."", ""reference"": ""PMID:33862140"", ""snippet"": ""Around 200 FSASD cases are reported worldwide, with the clinical spectrum ranging from a severe infantile onset form, often lethal in early childhood, to a mild, less severe form with subjects living into adulthood, also called Salla disease. The pathobiology of FSASD remains poorly understood and FSASD is likely underdiagnosed."", ""supports"": ""SUPPORT""}"
7165	6941	297	Schizophrenia	Schizophrenia.yaml	prevalence	0	evidence	0	PMID:18480098	PARTIAL		The rate ratio for males:females was 1.4:1. Prevalence estimates also show prominent variation.	While the male to female ratio of incidence is reported as 1.4:1, the abstract does not provide exact figures on the percentage of the population affected except that there is prominent variation. Therefore, the part of the statement with the percentage is not directly supported by this source.	"{""explanation"": ""While the male to female ratio of incidence is reported as 1.4:1, the abstract does not provide exact figures on the percentage of the population affected except that there is prominent variation. Therefore, the part of the statement with the percentage is not directly supported by this source."", ""reference"": ""PMID:18480098"", ""snippet"": ""The rate ratio for males:females was 1.4:1. Prevalence estimates also show prominent variation."", ""supports"": ""PARTIAL""}"
7237	6977	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	prevalence	0	evidence	0	PMID:35804238	SUPPORT	HUMAN_CLINICAL	Scimitar syndrome (SS) is a rare congenital condition which includes partial anomalous pulmonary venous return (PAPVR) and a variable degree of pulmonary hypoplasia.	Three-decade single-center series documenting the rarity of scimitar syndrome and its composite features.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Three-decade single-center series documenting the rarity of scimitar syndrome and its composite features."", ""reference"": ""PMID:35804238"", ""snippet"": ""Scimitar syndrome (SS) is a rare congenital condition which includes partial anomalous pulmonary venous return (PAPVR) and a variable degree of pulmonary hypoplasia."", ""supports"": ""SUPPORT""}"
7238	6977	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	prevalence	0	evidence	1	PMID:40046954	SUPPORT	HUMAN_CLINICAL	Scimitar syndrome is a rare disease has an incidence of approximately 1-3 per 100,000 live births.	Case report confirming the estimated incidence of 1-3 per 100,000 live births.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case report confirming the estimated incidence of 1-3 per 100,000 live births."", ""reference"": ""PMID:40046954"", ""snippet"": ""Scimitar syndrome is a rare disease has an incidence of approximately 1-3 per 100,000 live births."", ""supports"": ""SUPPORT""}"
7239	6977	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	prevalence	0	evidence	2	PMID:40110298	SUPPORT	HUMAN_CLINICAL	The incidence is estimated to be between 1 and 3 cases per 100 000 live births.	Independent confirmation of the 1-3 per 100,000 incidence estimate from a Sudanese case report.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Independent confirmation of the 1-3 per 100,000 incidence estimate from a Sudanese case report."", ""reference"": ""PMID:40110298"", ""snippet"": ""The incidence is estimated to be between 1 and 3 cases per 100 000 live births."", ""supports"": ""SUPPORT""}"
7329	7042	303	Sengers syndrome	Sengers_syndrome.yaml	prevalence	0	evidence	0	DOI:10.3389/fped.2021.639687	SUPPORT		Sengers syndrome (OMIM #212350) is a rare autosomal recessive disorder due to mutations in acylglycerol kinase (AGK) gene.	This case report describes Sengers syndrome as a rare disorder.	"{""explanation"": ""This case report describes Sengers syndrome as a rare disorder."", ""reference"": ""DOI:10.3389/fped.2021.639687"", ""snippet"": ""Sengers syndrome (OMIM #212350) is a rare autosomal recessive disorder due to mutations in acylglycerol kinase (AGK) gene."", ""supports"": ""SUPPORT""}"
7755	7506	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	prevalence	0	evidence	0	PMID:22037857	SUPPORT		 ...one case each of transient neonatal pustular melanosis... (2.3% each) were enrolled in this study...	The literature indicates that transient neonatal pustular melanosis is quite rare with only one case identified out of a cohort, supporting the statement that it has a rare prevalence in newborns.	"{""explanation"": ""The literature indicates that transient neonatal pustular melanosis is quite rare with only one case identified out of a cohort, supporting the statement that it has a rare prevalence in newborns."", ""reference"": ""PMID:22037857"", ""snippet"": "" ...one case each of transient neonatal pustular melanosis... (2.3% each) were enrolled in this study..."", ""supports"": ""SUPPORT""}"
7887	7592	331	Tuberculosis	Tuberculosis.yaml	prevalence	0	evidence	0	PMID:35577247	REFUTE		Globally, the prevalence rate of LTBI decreased from 30.66% in 1990 to 23.67% in 2019, with an AAPC of -0.9%.	The prevalence rate of latent tuberculosis infection (LTBI) is much higher than 0.1% globally, at approximately 23.67% as of 2019.	"{""explanation"": ""The prevalence rate of latent tuberculosis infection (LTBI) is much higher than 0.1% globally, at approximately 23.67% as of 2019."", ""reference"": ""PMID:35577247"", ""snippet"": ""Globally, the prevalence rate of LTBI decreased from 30.66% in 1990 to 23.67% in 2019, with an AAPC of -0.9%."", ""supports"": ""REFUTE""}"
7888	7592	331	Tuberculosis	Tuberculosis.yaml	prevalence	0	evidence	1	PMID:30454918	REFUTE		An estimated 1.7 billion (23%) of the world's population is infected with Mycobacterium tuberculosis leading to more than 10 million new tuberculosis (TB) cases each year.	The prevalence of tuberculosis infection is around 23%, much higher than the 0.1% suggested in the statement.	"{""explanation"": ""The prevalence of tuberculosis infection is around 23%, much higher than the 0.1% suggested in the statement."", ""reference"": ""PMID:30454918"", ""snippet"": ""An estimated 1.7 billion (23%) of the world's population is infected with Mycobacterium tuberculosis leading to more than 10 million new tuberculosis (TB) cases each year."", ""supports"": ""REFUTE""}"
7889	7592	331	Tuberculosis	Tuberculosis.yaml	prevalence	0	evidence	2	PMID:33296141	NO_EVIDENCE		Tuberculosis (TB) is a widespread disease that crosses the human and animal health boundaries, with infection being reported in wildlife, from temperate and subtropical to arctic regions.	This source discusses the prevalence of TB in wildlife but doesnt provide specific global prevalence rates in humans.	"{""explanation"": ""This source discusses the prevalence of TB in wildlife but doesnt provide specific global prevalence rates in humans."", ""reference"": ""PMID:33296141"", ""snippet"": ""Tuberculosis (TB) is a widespread disease that crosses the human and animal health boundaries, with infection being reported in wildlife, from temperate and subtropical to arctic regions."", ""supports"": ""NO_EVIDENCE""}"
7890	7592	331	Tuberculosis	Tuberculosis.yaml	prevalence	0	evidence	3	PMID:32324750	NO_EVIDENCE		A TB prevalence of 74.1 (95% CI 48.3-99.3) per 100,000 adult population for smear positive TB and 119.3 (95% CI 78.8-159.9) per 100,000 adult population for bacteriological confirmed MTB was estimated for Rwanda.	This source provides data specific to Rwanda not global prevalence rates.	"{""explanation"": ""This source provides data specific to Rwanda not global prevalence rates."", ""reference"": ""PMID:32324750"", ""snippet"": ""A TB prevalence of 74.1 (95% CI 48.3-99.3) per 100,000 adult population for smear positive TB and 119.3 (95% CI 78.8-159.9) per 100,000 adult population for bacteriological confirmed MTB was estimated for Rwanda."", ""supports"": ""NO_EVIDENCE""}"
7891	7592	331	Tuberculosis	Tuberculosis.yaml	prevalence	0	evidence	4	PMID:23219235	NO_EVIDENCE		Tuberculosis (TB) epidemiology is characterized by significant differences in prevalence between men and women worldwide, with cases among men exceeding those found in women by a ratio of 2:1 in some regions.	This source addresses sex differences in TB prevalence but not the global prevalence rate.	"{""explanation"": ""This source addresses sex differences in TB prevalence but not the global prevalence rate."", ""reference"": ""PMID:23219235"", ""snippet"": ""Tuberculosis (TB) epidemiology is characterized by significant differences in prevalence between men and women worldwide, with cases among men exceeding those found in women by a ratio of 2:1 in some regions."", ""supports"": ""NO_EVIDENCE""}"
8041	7681	333	Type I Diabetes	Type_I_Diabetes.yaml	prevalence	0	evidence	0	PMID:34599655	REFUTE		Global numbers of incident and prevalent cases of type 1 diabetes were estimated to be 234,710 and 9,004,610, respectively, in 2017...Globally, type 1 diabetes represents about 2% of the estimated total cases of diabetes.	The prevalence of type 1 diabetes globally is estimated to be around 2%, not 0.1-0.2%.	"{""explanation"": ""The prevalence of type 1 diabetes globally is estimated to be around 2%, not 0.1-0.2%."", ""reference"": ""PMID:34599655"", ""snippet"": ""Global numbers of incident and prevalent cases of type 1 diabetes were estimated to be 234,710 and 9,004,610, respectively, in 2017...Globally, type 1 diabetes represents about 2% of the estimated total cases of diabetes."", ""supports"": ""REFUTE""}"
8042	7681	333	Type I Diabetes	Type_I_Diabetes.yaml	prevalence	0	evidence	1	PMID:16085737	NO_EVIDENCE		The global prevalence of diabetes for all age groups is estimated to be 2.8%. Type 2 diabetes accounts for at least 90% of diabetes worldwide.	This study provides global prevalence data for diabetes in general and specifically mentions Type 2 diabetes but does not give a percentage for the prevalence of Type 1 diabetes.	"{""explanation"": ""This study provides global prevalence data for diabetes in general and specifically mentions Type 2 diabetes but does not give a percentage for the prevalence of Type 1 diabetes."", ""reference"": ""PMID:16085737"", ""snippet"": ""The global prevalence of diabetes for all age groups is estimated to be 2.8%. Type 2 diabetes accounts for at least 90% of diabetes worldwide."", ""supports"": ""NO_EVIDENCE""}"
8043	7681	333	Type I Diabetes	Type_I_Diabetes.yaml	prevalence	0	evidence	2	PMID:27959859	REFUTE		The incidence of childhood-onset type 1 diabetes has been increasing at a rate of 3%-5% per year globally...no means for a practical 'cure' exist.	The increasing incidence suggests a prevalence higher than 0.1-0.2%.	"{""explanation"": ""The increasing incidence suggests a prevalence higher than 0.1-0.2%."", ""reference"": ""PMID:27959859"", ""snippet"": ""The incidence of childhood-onset type 1 diabetes has been increasing at a rate of 3%-5% per year globally...no means for a practical 'cure' exist."", ""supports"": ""REFUTE""}"
8381	7945	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	prevalence	0	evidence	0	PMID:32914558	SUPPORT		Wolf-Hirschhorn syndrome (WHS) (OMIM#194190) is a contiguous gene syndrome with estimated prevalence being around 1 in 50,000 births.	This provides the birth prevalence estimate which translates to approximately 0.002% of the population.	"{""explanation"": ""This provides the birth prevalence estimate which translates to approximately 0.002% of the population."", ""reference"": ""PMID:32914558"", ""snippet"": ""Wolf-Hirschhorn syndrome (WHS) (OMIM#194190) is a contiguous gene syndrome with estimated prevalence being around 1 in 50,000 births."", ""supports"": ""SUPPORT""}"
8382	7945	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	prevalence	0	evidence	1	PMID:34572183	SUPPORT		Wolf-Hirschhorn syndrome (WHS), a rare disorder determined by distal 4p deletion, is characterized by a pre and postnatal growth retardation, hypotonia, intellectual disability, epilepsy, craniofacial dysmorphism, and congenital fusion anomalies.	This confirms Wolf-Hirschhorn syndrome is a rare disorder with characteristic features.	"{""explanation"": ""This confirms Wolf-Hirschhorn syndrome is a rare disorder with characteristic features."", ""reference"": ""PMID:34572183"", ""snippet"": ""Wolf-Hirschhorn syndrome (WHS), a rare disorder determined by distal 4p deletion, is characterized by a pre and postnatal growth retardation, hypotonia, intellectual disability, epilepsy, craniofacial dysmorphism, and congenital fusion anomalies."", ""supports"": ""SUPPORT""}"
